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Abstract
A number of selenium compounds have been shown to have anticancer properties. 
The mechanism by which selenium has anticarcinogenic effects is not understood 
although it is likely to be related to its ability to inhibit cell growth and induce 
apoptosis. The mechanism by which selenium compounds induce apoptosis is also not 
understood although it has been hypothesised that selenite induces cell death during 
its reduction to hydrogen selenide by the generation of reactive oxidant species 
resulting in oxidative stress. Bcl-2 has been shown to inhibit the ability of a number 
of stimuli to cause apoptosis possibly by its ability to prevent the effects of reactive 
oxygen species and peroxides. The aim of this project was therefore to investigate 
whether Bcl-2 could inhibit cell death induced by two selenium compounds; 
selenodiglutathione (SDG), the primary metabolite of selenite and 1,4- 
phenylenebis(methylene)selenocyanate (p-XSC), a novel synthetic selenium 
compound.
The first part of the thesis work describes the preparation of SDG and 
optimisation of conditions for growth inhibition by SDG and p-XSC. The second part 
of the thesis describes studies to test whether over-expression of Bcl-2 could protect 
cells from cell death induced by selenium compounds.
MCF7 cells, a human breast cell line, were transfected with a Bcl-2 expression 
vector by electroporation and selected for resistance to G418, the selection marker.
By western blotting of cell lysate and detection with anti-Bcl-2 antibodies, a number 
of clones were demonstrated to over-express Bcl-2 protein. By the use of cell 
proliferation and cloning assays it was demonstrated that clones over-expressing Bcl- 
2 protein were equally sensitive to cell death induced by selenium compounds SDG 
and p-XSC as cells transfected with vector control. As Bcl-2 over-expression in a 
haemopoetic cell line has previously been shown to protect against apoptosis induced 
by H2O2 , it was also tested if the clones produced in this study to over-express Bcl-2 
were able to prevent H20 2 induced cell death. From the results of the cell proliferation 
and cloning assays, cells with over-expression of bcl-2 did not appear to be more 
resistant to H2O2 induced cell death than control cells. Thus, in this study Bcl-2 over­
expression was found not to provide protection against SDG, p-XSC or H2O2 induced 
cell death in MCF7 cells.
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11. Introduction
1.1 Selenium - an essential trace element
Selenium is an essential trace element which occurs naturally in the diet. It is best 
absorbed by plants as selenates and to a lesser degree as selenites (Spallholz 1994). It 
is particularly abundant in foods such as fish, butter, Brazil nuts and cereal crops 
although variation of selenium in food content occurs depending on the selenium 
status of the region in which it originated (Trimmer et al. 1988). The selenium 
component in plants is predominantly selenomethionine (Olson et al., 1970) although 
selenium in the form of selenocysteine can also be obtained from animal food sources 
and bacterial processed foods.
A number of proteins have been identified in which selenium is incorporated 
as a selenocysteine molecule, including four forms of glutathione peroxidases, types- 
I, II and III-iodothyronine deiodinase, selenoprotein P, thioredoxin reductase and 
selenoprotein W. The selenocysteine in such selenoproteins differs from selenium 
randomly incorporated into proteins as a replacement for sulphur in cysteine in that it 
is encoded from a specific selenocysteine codon, UGA. The mechanism by which 
selenium becomes incorporated in to proteins is described in section 1.2. The 
selenocysteine has been shown to be essential for the activity of these proteins thus 
establishing a biological role for selenium (Berry et al. 1991; Hill et al. 1997).
Selenium deficiency has been associated with heart muscle damage as low 
selenium blood levels have been implicated in Keshan disease in rural China causing 
death of children aged 1-10 years old (Jackson 1987). High levels of selenium intake 
by cattle and sheep following consumption of seleniferous plants can cause toxic 
conditions known as ‘alkali disease’ and ‘blind staggers’ characterised by hair loss, 
loss of hoofs and deformation (Spallholz et al. 1994).
The US National Research Council has analysed data produced by Chinese 
Scientists in order to issue a Recommended Daily Allowance (RDA) of 70 pg and 
55 pg of selenium per day for men and women, respectively (Levander. 1991). This 
dietary allowance was calculated on the basis of selenium levels required to saturate 
glutathione peroxidase activity and did not take in to account the levels of any other
2selenoproteins or levels of selenium required to have chemopreventive effects (see 
section 1.4)
1.2 Selenoprotein synthesis
Glutathione peroxidase (GPX) was the first mammalian selenoprotein to be 
discoverved containing selenium in the form of selenocysteine (Rotruck et a l 1973). 
By sequencing the GPX gene and mRNA it was shown that the selenocysteine at the 
active site was encoded a by TGA codon (Chambers et al. 1986). What distinguishes 
a UGA stop codon from a UGA which codes for selenocysteine cotranslational 
insertion has yet to be fully determined. E.coli dehydrogenase is a selenoprotein 
encoded by the gene fdhY (Zinoni et al. 1987). A stem loop on the fdhF mRNA 
immediately 3’ of the UGA codon has been shown to be necessary for selenocysteine 
incorporation (Zinoni et al. 1990), with changes of a single base substantially 
decreasing selenocysteine incorporation (Heider et al. 1992).
The mechanism by which selenium is incorporated in to selenoproteins is 
thought to be similar in eukaryotic and prokaryotic cells although this has yet to be 
fully determined. Inorganic forms of selenium are more easily incorporated as 
selenocysteine in glutathione peroxidases than selenium administered as 
selenocysteine (Sunde et al. 1987). Labelling of amino acids showed that the 
selenocysteine in the carbon skeleton of glutathione peroxidase was derived from 
serine and not from selenocysteine or cysteine. This puzzle has now been explained 
by recent characterisation of mutant E.coli unable to synthesise the selenoprotein 
formate dehydrogenase and enabled the identification of four genes involved in 
selenocysteine cotranslation (Burk et al. 1991). SelC encodes a tRNAsersec that 
associates with the UGA codon and binds L-serine catalysed by Seryl-tRNA ligase. 
The side chain oxygen of serine is activated before replacement with selenium. SelA 
mutants were unable to convert seryl-tRNAser sec to selenocysteyl tRNAser sec.
Addition of Sel A, now shown to code for selenocysteine synthase, resulted in the 
consumption of activated serine and the appearance of an unidentified selenium 
compound. Further addition of Sel D and selenite resulted in the disappearance of the 
unidentified selenium compound and the appearance of selenocysteine. The Sel D
product in mammals has now been identified as selenophosphate synthetase which 
generates selenophosphate, the active donor to the tRNA (Low et al. 1995). Bacterial 
and human selenophophate synthetases were shown to be functional in higher 
eukaryotes and bacteria.
SecSelenide Serine tRNA
Selenophosphate 
synthetase
Seryl-tRNA
synthetase
Selenophosphate
S e c
seryl- tRNA
T
[Se]Cys
5 '
Av U 
C
UGA 3 '
F i g u r e  1.1
Proposed mechanism of selenocysteine incorporation into prokaryotic selenoproteins. 
A specific tRNA recognises the UGA sequence as a selenocysteine codon (due to the 
3'loop structure) and binds L-serine. The side chain o f  serine is activated and replaced 
with selenium to form selenocysteine (Adapted from Low and Berry. 1996).
4However, the human selenophosphate synthetase was only partially able to 
complement the bacterial system, suggesting that additional factors found in 
mammalian cells but not bacterial cells are required for the function of human 
selenophosphate synthetase activity. Sel B is a selenocysteine-specific elongation 
factor necessary for the incorporation of selenocysteine in to bacterial proteins.
1.3 Selenoproteins
Formation of peroxides and free radicals in the cell results in lipid peroxidation and 
hence loss of membrane integrity. Glutathione peroxidases utilise reduced glutathione 
to reduce hydrogen peroxide and organic hydroperoxides and are thus able to protect 
cells from oxidative damage.
There are currently four glutathione peroxidases known to exist. The first to 
be discovered is referred to as classical glutathione peroxidase (cGPx) and was shown 
in the presence of glucose to protect erythrocytes from hydroperoxide induced 
damage (Cohen and Hochenstein. 1963). Glucose is required to generate NADPH and 
thus enable the reduction of oxidised glutathione by glutathione redutase which can 
then be utilised by the glutathione peroxidase enzyme.
The second member of the glutathione peroxidase family to be discovered 
was phospholipid hydroperoxide glutathione peroxidase (PHGPx). Maiorino and 
coworkers were the first to identify PHGPx in human cells (Maiorino et al. 1991). By 
investgating GPx activities in 7 tumor derived cell lines they showed differential 
activities of cGPx and PHGPx indicating that expression of these two proteins is 
independent of each other. Both cGPx and PHGPx are present in the cytosol of cells.
However, the third member of the glutathione peroxidase (GPx3) is found in 
the plasma and is appropriately named plasma glutathione peroxidase (pGPx) 
(Maddiparti et al. 1987; Takayashi et al. 1986). As the concentration of glutathione is 
100-fold less in the plasma than it is in the tissues the mechanism of action of pGPx is 
not understood and therefore raises the possibility that another thiol other than 
glutathione, such as thioredoxin, is utilised.
These enzymes differ in primary structure, localisation and substrates 
specificity. cGPx and pGPX are both tetramers consisting of 4 identical subunits each 
containing a single selenocysteine whereas PHGPx exists as a monomer containing
5one selenocysteine molecule (Maiorino et al. 1991; Forstorm et al. 1978). 
Investigations of the reactions of these enzymes with various substrates revealed that 
they have different substrate specificity's (Yamamoto and Takahashi. 1993). Plasma 
GPx is able to reduce organic and hydroperoxides but has 10% of the activity that 
classical GPx was shown to have. Both plasma GPx and phospholipid GPx are able to 
cause immediate reduction of phosphatidylcholine hydroperoxide, whereas cellular 
GPx can not. Cytosolic GPx was shown to have little activity in reducing peroxides in 
erythrocyte phospholipid ghosts. Plasma GPx caused almost complete reduction of 
two major membrane phosholipids, phosphatidyl choline and 
phophatidylethanolamine but was unable to reduce cholesterol hydroperoxides. 
Phospholipid GPx was capable of reducing almost all of the peroxides in the 
erythrocyte phospholipid ghosts. The most recently identified member of the 
glutathione peroxidase family, gastrointestinal glutathione peroxidase (GPx-GI) was 
isolated from human hepatocyte cells and is thought to be a tetrameric protein 
localised in the cytosol (Chu et al. 1993). It has similar substrate specificity to cGPx as 
it is able to catalyze the reduction of H20 2, tert-butyl hydroperoxide, cumene 
hydroperoxide and linoleic acid hydroperoxide but cannot reduce phosphatidyl 
hydroperoxide. Chu and coworkers (1993), demonstrated that GPx-GI is readily 
detected in human liver, colon, small intestine and stomach, but is not found in other 
tissues such as kidney, lung, heart, placenta or uterus. A possible role of GPx-GI is to 
protect against ingested toxic lipid peroxides.
Like glutathione peroxidase, the selenoenzyme Type 1 iodothyronine 
deiodinase (5TDI) is an oxidoreductase and requires thiols for its activity. It is found 
mainly in the liver and kidney and is required for the conversion of thyroxine 
(3,5,3’,5'-tetraiodothyronine, T4) to 3,5,3'-triiodothronine (T3) (Larsen et al. 1981). 
Sequencing of this enzyme determined that like the glutathione peroxidases the 
selenocysteine present in type 1 iodothyronine deiodinase is encoded for by a UGA 
codon present in the mRNA and that the selenocysteine is required for maximum 
activity of the enzyme (Berry et al. 1991).
Selenoprotein P is the first selenoprotein identified to contain more than one 
selenocysteine molecule. Analysis of the amino acid content suggests that each 
selenoprotein P molecule contains 7.5 selenocysteine molecules (Read et al. 1990).
6However the sequence of the cDNA predicts 10 selenocysteines per selenoprotein P 
molecule, as the cDNA contains 10 TGA codons in its open reading frame (Hill et al. 
1991). It is possible that some of the selenocysteines are lost during purification 
procedures or alternatively one of the TGA codons near the end of the sequence could 
behave as a stop codon giving a shorter protein than first expected. The function of 
selenoprotein P is not known although an important role can be inferred by the fact 
that it contains greater than 60% of the plasma selenium (Read et al. 1990). It has 
also been reported to incorporate selenium and be synthesized preferentially over 
glutathione peroxidase when selenium levels in selenium-deficient rats are repleted 
(Burk et al. 1991, Yang et al 1987). Selenoprotein P has been suggested to act as a 
transporter of selenium from the liver to the peripheral tissues based on the 
observation that radiolabelled selenium initially taken up by the liver is incorporated 
in to selenoprotein P before it accumulates in tissues (Motsenbocker and Tappel. 
1982). However, since selenoprotein P contains covalently bound selenium molecules 
and since the selenium status of animals has no effect on the disappearance of 
radiolabelled selenium from the plasma, it seems unlikely that dominant role of 
selenoprotein P is to act as selenium transporter (Burk et al. 1991). Although 
selenoprotein P was first discovered in the plasma it has since proven to be more 
widespread throughout the body and has been identified in the liver, spleen, testis, 
kidney and heart (Motsenbocker and Tappel. 1982). Selenium-deficient rats were 
shown to increase selenium uptake by the brain 12-fold when injected with 
radiolabelled selenoprotein P, whereas no increased uptake of selenium was observed 
in the heart or skeletal muscle or when radiolabelled selenium was administered in 
the form of glutathione peroxidase, suggesting a specific mechanism of uptake of 
selenoprotein P by the brain (Burk et al. 1991). A role as an antioxidant has also been 
suggested for selenoprotein P since administration of selenium to selenium-deficient 
rats protects against lipid peroxidation and liver necrosis induced by treatment with 
diquat (Burk et al. 1980). As selenoprotein P has been demonstrated to be restored 
more rapidly than glutathione peroxidases, it is hypothesised that it is selenoprotein P 
that is responsible for the observed protection against diquat following administration 
of selenium (Burk et al. 1991). The presence of many histidines and cysteines, which 
are known to be capable of metal binding in other proteins, and thiol groups in
7selenoprotein P indicates the possibilty of redox-active sites, thus further suggesting a 
role for selenoprotein P as an antioxidant (Read et a l 1990).
Selenoprotein W was purified from rat muscle (Vendeland et al. 1993) and 
mRNA levels have been shown to alter in response to selenium status (Vendeland et 
a l 1995). The exact function of selenoprotein W is not known although its function 
could possibly be linked to skeletal and heart muscle myopathies observed in cases of 
selenium deficiency.
Although thioredoxin reductase is not a recently discovered protein it has only 
recently been identified as a selenoprotein (Gladyshiev et a l 1996). On the initial 
sequencing of this protein the UGA codon found close to the end of the mRNA 
sequence was interpreted to be a termination codon; however it is now known to 
encode a selenocysteine as the penultimate amino acid. This selenocysteine has 
recently been shown to be necessary for thioredoxin reductase activity (Hill et a l 
1997) The thioredoxin system has an essential role in the production of DNA 
precursors and regulation of the activity of various proteins by reduction of protein 
disulphide groups.
Investigation of the activity and mRNA levels of cytosolic GPX (cGPX), 
PHGSH-Px and 5’IDI in rat liver following selenium depletion revealed that the 
abundance of the mRNA for cGPx and its activity was greatly reduced whereas the 
activity of PHGPx and 5’EDI and their mRNA levels were maintained (Bermano et a l  
1995). These selenium deficiency experiments in the rat have also shown that 
selenoprotein activity is differentially maintained in different tissues. The activities of 
PHGSH-Px and 5’ IDI were found to be substantially reduced in the liver whereas in 
the thyroid gland the activity of PHGPx was found to be maintained and the activity 
of 5’EDI was increased. These results demonstrate that in conditions of selenium 
deficiency, not only are certain selenoproteins preferentially maintained at the 
expense of others, but there is also differential regulation of mRNA abundance and 
activity of each selenoprotein between tissues. Bermano et a l (1995) demonstrated 
that the transcription of the genes for cGPx, PHGPx and 5’EDI was not effected by 
selenium deficiency. It was therefore suggested that differential regulation of different 
selenoproteins was a result of differential stability of their mRNA. Further work by 
Bermano et a l (1996) studied the effect of the untranslated region on the mRNA of
8cGPx, PHGPx and 5TDI on the efficiency and translation of 5’LDI in rat hepatoma 
cells. Under conditions of selenium depletion, the untranslated region of cGPx was 
found to cause a greater reduction in the levels of 5’IDI than the untranslated region 
of PHGPx or 5’EDI. On repletion of selenium levels, the translation efficiency of the 
cGPx and PHGPx untranslated regions were found to be similar but the efficiency of 
the 5”IDI untranslated region was found to be much more efficient. Thus it was 
demonstrated that the insertion of selenocysteine is regulated by the efficiency of the 
untranslated region of the mRNA.
1.4 Chemopreventive effects of selenium 
1.41 Animal Work
Several studies in which selenium has been administered to the diet of animals have 
shown selenium to inhibit carcinogenesis in various tissues including the stomach 
(Kobayashi 1986), pancreas (Kise et al. 1990), colon (Jacobs 1983; Banner et al. 
1984), mammary gland (Ip 1981, Thompson and Becci 1980) and skin (Perchellet et 
al. 1987). Banner and co-workers (1984) showed that inhibition of tumour formation 
was greater in the proximal colon than in the distal colon and that this was correlated 
to selenium uptake and accumulation. Selenium uptake was also found to be higher in 
the mucosa than in muscle which is considered to be more beneficial since tumors 
induced by carcinogens are far more common in the mucosal tissues. In most studies, 
selenium is administered in the form of sodium selenite and this has been 
demonstrated to inhibit both chemically and virally induced carcinogenesis as well as 
growth of transplanted tumours (Milner 1985; Jacobs et al. 1983; Kobayashi 1986). 
Sodium selenite has been shown to inhibit carcinogenesis induced by chemical agents 
which require metabolic activation such as 2-acetylaminofluorene and 
dimethylhydrazine (Jacobs 1981; Jacobs et al. 1983) as well as direct acting 
carcinogens such as N-methyl-N-nitrosourea (MNU) (Thompson and Becci 1980) and 
N-methyl-N'nitro-N-nitrosoguanidine (MNNG), (Kobayashi 1986). Therefore, selenite 
must act to reduce tumour formation by a mechanism other than just effecting 
metabolic activation of carcinogens.
9In a rat mammary tumour model in which carcinogenesis was initiated by 
DMBA and promoted by feeding the rats a high fat diet, sodium selenite was shown 
to inhibit both the initiation and promotional stages of carcinogenesis (Ip. 1981). 
Sodium selenite was able to inhibit the promotional phase of carcinogenesis but more 
effectively inhibited the initiation phase. Maximal inhibition of tumorigenesis was 
achieved by administration of sodium selenite two weeks prior to DMBA treatment 
and continuously during the course of the experiment. Studies investigating the stage 
specificity of selenium inhibition in the mouse mammary tumour model demonstrated 
that the initiation phase of carcinogenesis is more sensitive than the post-inititation 
phase (Medina and Lane 1983). The progression of established tumours was relatively 
insensitive (Medina and Shepherd 1981).
1.4.2 Epidemiological Studies
A number of studies comparing plasma selenium levels of cancer patients with 
controls matched for age, sex, and smoking, have found a lower selenium plasma 
concentration in cancer patients compared with controls (Salonen et al. 1984; 
Jaskievich et al. 1988). However other studies have found no significant difference in 
plasma concentrations of selenium between cases and controls (Menkes et a l 1986; 
Overad 1991). Plasma selenium concentration is subject to intra-individual variation 
and represents the individual’s selenium consumption over a period of days to weeks. 
Measurement of selenium levels in toenails is a much more accurate measure of long­
term selenium intake by an individual as it represents selenium intake over a period of 
up to 18 months prior to clipping. A case control study in patients diagnosed to have 
oral cancer which measured selenium levels in toenails found a negative correlation 
with selenium concentration and cancer risk (Rogers et al. 1991). A disadvantage of 
case control studies is that it is not possible to ascertain if the low selenium levels 
observed in the cancer patients is a result of the cancer rather than the cause of it. 
Tumours have been shown to sequester vitamins so it is possible that a large tumour 
could cause a decrease in plasma levels. Alternatively it may be that dietary habits of 
a cancer patient alter following onset of the disease.
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A more reliable method to investigate the association of selenium levels and 
cancer risk is to set up prospective cohort studies since this type of study excludes the 
possibility that low selenium levels are caused by cancer. Sera collected in 1973 as 
part of the Hypertension Detection and Follow up Program in the USA provided a 
means of analysing selenium concentrations in sera, 5 years following collection from 
4480 individuals. (Willett and Stampfer 1983). A small but significant increase in 
cancer risk was associated with low selenium levels and this effect was strongest 
when levels of other nutrients such as vitamin E and carotenoids were low. The 
strongest associations were observed for cancers of the lung, gastrointestinal tract and 
haematological cancers. Other prospective cohort studies have found inverse 
relationships with selenium levels and cancer risk in haematological, (Salonen et al. 
1984, Ringstad et al. 1988), gastrointestinal (Salonen et al. 1984) and lung cancers 
(van de Brandt et al. 1993). An inverse relationship between serum selenium 
concentrations and subsequent cancer risk was observed in the stomach and 
oesophagus but not in the colon and rectum and this association was stronger for men 
than in women (Knekt et al. 1988).
Epidemiological studies generally show only weak associations between 
selenium intake and cancer risk. A number of prospective studies have found no 
significant association between cancer risk and selenium levels (Virtamo et al. 1987, 
Nomura et al. 1987). This type of study has many limitations: although it is possible 
to select age and sex matched controls and adjust figures according to factors such as 
smoking and weight, there are still many variables that are unaccounted for, such as 
the vast variation in consumption of other foodstuffs, genetic predisposition, exercise 
and environmental factors. It is also argued that persons with high levels of selenium 
intake tend to have a healthy diet in general such as one high in vegetables and fish, 
and therefore have a higher intake of other vitamins and minerals which may also 
contribute to the observed reduction in the risk of cancer. More convincing evidence 
for the anticarcinogenic ability of selenium has been provided by in vivo studies in 
which variation between individual animals is more controlled.
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1.4.3 Clinical Intervention Trials
A nutrition intervention trial in Linxian County, China, which has one of the world’s 
highest rates of oesophageal and gastric cardia cancer, investigated the 
chemopreventive effects of four combinations of nutrients: 1) retinol and zinc,
2) riboflavin and niacin, 3) vitamin C and molybdenum and 4) beta carotene, vitamin 
E and selenium (Blot et al. 1993, Taylor et al. 1994). A significant decrease in 
mortality rate was observed in the participants receiving supplements of beta 
carotene, vitamin E and selenium and this reduction could be attributed mainly to a 
lower incidence of cancer rates, particularly cancer of the stomach. No significant 
effects on mortality rate were observed for any of the other treatment groups. 
However, as selenium was administered with vitamin E and beta carotene in this trial 
it is not possible to a ascertain whether selenium has chemopreventive effects per se.
Three intervention trials were set up in areas of China which have a high 
incidence of primary liver cancer (PLC) (Yu et al. 1991). The first trial in which table 
salt fortified with 15 ppm sodium selenite showed a decrease in PLC incidence of 
34% after 5 years of supplementation, whereas no decrease in PLC incidence was 
seen in control populations which were without selenium supplementation. In the 
second study, 200 pg of selenium per day was given to hepatitis B virus surface 
antigen carriers in the form of a selenized yeast tablet. After 4 years, 5 of the 113 
subjects in the control group receiving placebo had developed primary liver cancer, 
whereas there was no incidence of PLC in the 113 subjects taking the selenium 
tablets. The third intervention trial in China involved the supplementation, to persons 
from families with a high incidence of PLC, with 200 pg of selenium as selenium 
yeast tablets. At the end of a two year study 1.26% of the control group had developed 
PLC compared to only 0.69% in the selenium supplemented group.
An intervention trial in which 200 pg per day of selenium as yeast tablets was 
administered for an average of 4.5 years to approximately 1300 patients with a history 
of basal cell or squamous cell carcinoma found no significant effect of selenium on 
the further occurrence of basal cell or squamous cell cancer (Clark et al. 1996). 
However, a significant reduction in total cancer mortality and also cancers of the 
lung, colorectal and prostate were found to be significantly reduced on administration
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of selenium. These studies provide more encouraging evidence for the potential of 
selenium to act as a chemopreventive agent.
1.5 Metabolism of selenite
Selenium in soils is more easily absorbed by plants as selenate than selenite 
(Spallholz et al. 1994). In plants selenate which is more toxic than selenite, is reduced 
to selenite and then metabolised in a pathway analogous to sulphur metabolism. In 
bacteria and animals a highly specific pathway for the metabolism of selenium exists.
Figure 1.2
Mechanism proposed by Seko et al. 1989 for the generation of superoxide anion from 
the mixture of selenite (Se03 ') and reduced glutathione GSH.
Inorganic selenite is reduced to form a selenopersulphide derivative via 
selenodiglutathione (SDG or GSSeSG) by the reaction proposed by Seko et al. (1989) 
(Figure 1.2). The selenopersulphide is formed by either direct reduction of selenite by 
glutathione reductase or spontaneously in the presence of excess glutathione (Ganther 
1971). The selenopersulphide derivative undergoes a further reduction to hydrogen 
selenide which can be channelled in to the synthesis of selenoproteins. Alternatively it 
can undergo a series of methylation reactions by thiol-S-methyltransferase to form 
dimethylselenide and the trimethylselenonium ion in order to be excreted (Mozier et 
al. 1988; Ganther 1971) (Figure 1.3). Dimethylselenide is exhaled in the breath
(Burk 1991).
4GSH GSSG GSH GSSG GSH GSSG o 2 0 2*
■►GSSeSG GSSeH
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whereas the trimethlyselenonium ion as well as inorganic and monomethylated forms 
of selenium are excreted in the urine (Vadhanavikit et al. 1993).
Evidence has been reported for metabolism in the back direction since 
animals administered trimethylselenonium have been shown to exhale 
dimethylselenide (Foster et al. 1986a). Dimethylated forms of selenium such as 
selenobetaine and selenobetainemethylester administered to the rat has been shown to 
result in substantial excretion of monomethylated and inorganic forms of selenium 
thus providing further evidence that demethylation is an important step in the 
metabolism of selenium compounds (Foster et al. 1986b).
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Selenite
General body proteins 
A
selenomethionine
selenocysteine
Selenodiglutathione
GSSeSG
Selenopersulphide
GSSeH
Hydrogen Selenide 
H?Se
Methyl selenol 
CHiSeH
Incorporation into 
selenocysteine 
proteins through 
the TGA codon
selenobetaine
Se-methylselenocysteine
Dimethyl selenide 
CH3SeCH3 +
Selenobetaine methyl ester
Dimethylselenoxide
Trimethylselenonium ion
(CH3)3 Se+
Figure 1.3
The metabolic pathway of selenite showing the entry of various seleno-compounds in 
to the pathway. Diagram adapted from (Ip. 1988) and (Lanfear et al. 1994).
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1.6 Anticarcinogenic properties of selenium are related to its metabolic form
The metabolic form of selenium is critical for its ability to prevent carcinogenesis. A 
study of several selenium compounds in a dimethylbenz(a)anthracene (DMBA)- 
induced mammary tumour model in the rat found the order of potency with regard to 
the ability of the compound to reduce tumour incidence as follows: Se- 
methylselenocysteine> selenite> selenocysteine> dimethylselenoxide (Ip et a l 1994). 
This study also investigated the ability of various selenium compounds to restore 
glutathione peroxidase activity following selenium deprivation. Selenite and Se- 
methylselenocysteine were found to be the most effective in restoring glutathione 
peroxidase activity, whereas dimethylselenoxide was moderately effective. 
Trimethylselenonium was considerably less effective in the restoration of glutathione 
peroxidase activity, however at very high concentrations complete recovery could be 
achieved. As glutathione peroxidase is synthesised via hydrogen selenide this 
provides further evidence for demethylation as trimethylselenonium would need to be 
demethylated to form hydrogen selenide.
Certain mono and dimethylated selenocompounds, such as Se- 
methylselenocysteine and selenobetaine, have greater anticarcinogenic activity 
compared to selenite, yet the trimethylated selenocompound, trimethylselenonium 
ion, is relatively inactive. This suggests that the critical active selenium metabolite 
involved in the prevention of carcinogenesis is produced after selenite has been 
introduced in to the pathway, but before it is metabolised to the relatively inactive 
excretory products. This is supported by experiments in which arsenite was 
coadministered with selenium compounds. Arsenite inhibits the microsomal enzyme 
thiol-S-methyltransferase, which utilises S-adenosylmethionine to methylate hydrogen 
selenide or methylselenol to form dimethylselenide (Mozier et a l 1988) Arsenic has 
been shown to have no effect on mammary carcinoma formation per se, yet low 
levels of arsenite decrease the anticarcinogenic effects of inorganic selenite, whereas 
it potentiates the effects of methylated selenium compounds (Ip and Ganther 1990). 
This supports the conclusion that partially methylated selenium compounds have the 
greatest anti-cancer effect since coadministration of arsenic with selenium
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compounds such as selenite and selenobetaine should result in the accumulation of 
partially methylated selenium metabolites, such as methylselenol.
1.7 Apoptosis
In living organisms there is a continuous turnover of cells in which old cells are 
replaced with new. Over-production of cells, or insufficient cell death, could have 
catastrophic effects on the organism, such as hyperplasia or tumour formation: it is 
therefore important that both these processes are closely regulated. There are two 
possible ways by which cells are known to die: necrosis and apoptosis (reviewed by 
Wyllie 1993). Necrosis occurs in response to a severe toxic cellular trauma, such as 
hypothermia or hypoxia. Swelling of the mitochondria and endoplasmic reticulum 
occurs followed by lysis of the cell as a result of the failure of plasma membrane ion 
transport mechanisms. The cytoplasmic contents of the cell are released into the 
extracellular fluid, including lysosmal enzymes which have the potential to damage 
the surrounding tissues and cause an inflammatory reaction.
In contrast, apoptosis is characterised by certain morphological cellular 
changes such as shrinkage in volume, rounding up caused by a loss of contact with 
neighbouring cells, membrane blebbing which is possibly a result of vesicles from the 
endoplasmic reticulum or golgi apparatus fusing with the plasma membrane and 
releasing their contents (Kerr et al. 1972). This results in a reduction in cellular 
volume and condensation of chromatin beneath the nuclear membrane. Apotosis is an 
active process, since inhibitors of RNA and protein synthesis, such as actinomycin D 
and cycloheximide, have been shown to inhibit apoptosis (MacDonald and Lees 1990; 
Martin et al. 1988). Activation of an endonuclease results in the cleavage of 
chromatin between nucleosomes which give the characteristic ‘DNA ladder’ when 
DNA from apoptosing cells is loaded on to an agarose gel and separated by 
electrophoresis (Duke et al. 1983). The endonuclease is activated by Ca and 
inhibited by Mg2+. Most of the organelles remain intact and the cell itself fragments 
into membrane bound apoptotic bodies which are phagocytosed by adjacent cells or 
nearby macrophages without inducing an inflammatory response. Thus, apoptosis 
does not result in damage to surrounding tissues.
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Apoptosis is responsible for the destruction of thymocyte clones which 
recognise self-antigens (Macdonald et al. 1990) and occurs to remove excess neurons 
in the brain during development: those neurons unable to obtain sufficient nerve 
growth factor (NGF) of brain-derived neurotrophic factor undergo apoptosis in the 
developing brain (Martin et al. 1988).
A number of genes associated with the regulation of apoptosis have been 
shown to be involved in the formation of tumours. The ability of wild type p53 to act 
as a tumour supressor gene by inducing apoptosis is lost by mutation, in greater than 
50% of cancers (Hollstein et al. 1991). Mutations of p53 are common in a wide range 
of cancers including cancers of the lung, colon, oesophagus, breast, liver and 
haemopoetic tissues (Hollstein et al. 1991). Overexpression of the apoptosis- 
inhibitory protein Bcl-2 and its homologue mcl-2 induced by the Epstein Barr protein 
latent membrane protein-1 (LMP-1) has been implicated in Burkitf s Lymphoma 
(Wang et a l 1996). Fas, a member of the Tumour Necrosis Factor (TNF) receptor 
super-family has been shown to induce apoptosis (Itoh et al 1991; Oehm et al. 1992). 
A family of proteases named Interleukin- lB-converting enzyme (ICE)-like proteases, 
has been identified and shown to be involved in Fas and TNF mediated apoptosis 
since inhibitors of this proteases are able to inhibit apoptosis induced by Fas or TNF 
(Enari et a l 1995; Los et a l 1995).
1.8 The involvement of the Bcl-2 family of proteins in regulating apoptosis
Bcl-2 was first discovered in human follicular lymphomas containing a t(14;18) 
chromosomal translocation (Tsujmoto and Croce 1985). More recently Bcl-2 has been 
shown to prevent apoptosis in a number of cell lines including haemopoetic, human 
breast, rat fibroblast and Chinese Hamster ovary cell lines when induced by a variety 
of different stimuli, yet its mechanism of action is not yet understood (Hockenbery et 
al 1993; Lee et al. 1997; Pourzand et al. 1997; Bissonnette et al. 1992). A number of 
apoptosis-inducing compounds have been reported to inactivate or down regulate Bcl- 
2, such as the differentiation- and apopotosis- inducing agent sodium phenylacetate in 
a human malignant breast cell line (Adam et al. 1995). Apoptosis in MCF7 cells 
induced by treatment with taxol results in phosphorylation and inactivation of Bcl-2
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(Blagosklonny et al. 1996). It was also shown that taxol reduced the coprecipitation 
of Bcl-2 with Raf-1, thus activating Raf-1; moreover, Raf-1 was necessary for the 
taxol induced phosphorylation and inactivation of Bcl-2, since this was prevented 
when Raf-1 was depleted by administration of benzoquinone.
Transgenic mice producing the human bcl-2 gene in hepatocytes were shown 
to be greatly protected from hepatic failure due to massive hepatocyte apoptosis 
following treatment with the agonistic anti-Fas antibody (Lacronique et a l 1996).
Bcl-2 is a 25 kDa protein and it has been shown to be localised on 
mitochondria, nuclear membranes and endoplasmic reticulum. Since these are all 
sites of free radical generation it is possible that Bcl-2 may interfere with the 
production or effects of free radicals (Hockenberry et al. 1990; Krajewski et al. 
1993). Immunolocalisation studies in subcellular fractions of cells revealed that the 
majority of Bcl-2 was located on the mitochondrial membrane rather than in 
fractions containing the plasma membrane or golgi apparatus (Hockenbery et al. 
1990). As the major functions of the inner mitochondrial membrane include oxidative 
phosphorylation, as well as electron and metabolite transport mechanisms, it is not 
unreasonable to hypothesise that Bcl-2 could regulate one of these mechanisms. Bcl-2 
contains a hydrophobic sequence in its C-terminus which has been shown to act as an 
anchor segment required to locate the protein to its outer mitochondrial membrane 
position (Nguyen et al. 1993). Studies with a vector expressing Bcl-2 protein lacking 
the C-terminal anchor sequence showed that this truncated protein was mis-localised 
throughout the entire cytosol in contrast to full length protein which is found to be 
bound to mitochondria (Hockenbery et al. 1993). However, although the truncated 
form of Bcl-2 is not localised to the mitochondrial membrane it was still able to 
protect the LL-3 dependant haemopoetic cell line FL5.12 from apoptosis on LL-3 
withdrawal although it was not as effective as full length Bcl-2. Thus, although Bcl-2 
functions more efficiently when intergrated into the mitochondrial membrane, this is 
not essential for its activity (Hockenberry et al. 1993).
Over expression of Bcl-2 has been shown to prevent c-myc induced cell death 
in a multi-drug resistant human breast cell line and Chinese Hamster Ovary cells 
(Bissonnette et al. 1992; Lee et al. 1997). Investigation of the effects of Bcl-2 on the 
apoptotic and mitogenic functions of c-myc was investigated in Rat-1 fibroblast cells
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(Fanidi et al. 1992). c-myc was activated by serum depletion and addition of p- 
oestradiol in fibroblast cells resulting in apoptosis. However, c-myc induced 
apoptosis was completely inhibited in Rat-1 fibroblasts in which Bcl-2 was 
overexpressed, whereas the proliferation rate in low serum, under the control of c- 
myc activated by (3-oestradiol, was not effected. These experiments suggest that Bcl-2 
can selectively inhibit the apoptosis-inducing abilities of c-myc without affecting its 
ability to promote proliferation.
Bcl-2 is thought to inhibit apoptosis induced by UVA radiation in a rat 
fibroblast cell line (R6) by acting as an antioxidant. Treatment of R6 cells with UVA 
radiation results in the upregulation of the heme oygenase 1 (HO-1) gene by inducing 
oxidative stress (Keyes et al. 1989). Over expression of Bcl-2 has been shown to 
protect against UVA induced radiation and inhibit the upregulation of the HO-1 gene 
(Pourzand et a l 1997). Thus it was hypothesised that Bcl-2 can prevent the generation 
of reactive oxygen species or is protective against their effects.
Bcl-2 has been shown to protect a human lymphoid cell line and an IL-3 
dependant murine pro-B cell line (BAF3) against apoptosis induced by a monoclonal 
anti-APO antibody and a neutralising monoclonal anti IL-3 antibody respectively, 
under hypoxic conditions (Jacobson et a l 1995). As the generation of reactive oxygen 
species is small under hypoxic conditions it was hypothesised that the protective 
effect of Bcl-2 may be attributed to interference with apoptotic induction pathways 
rather than the production of reactive oxygen species.
Bcl-2 protects against dexamethasone induced lipid peroxidation (Hockenbery 
et a l 1993). Incubation of T cell hybridoma, 2B4 cells, with the polyunsaturated 
fluorescent fatty acid, cis-parinoic acid, leads to its incorporation in to the lipid 
membrane and there it provides a measure of oxidative stress as fluorescence is lost 
on lipid peroxidation. Treatment of these cells with dexamethasone resulted in loss of 
fluorescence and therefore presumably generation of reactive oxygen species. No loss 
of fluorescence was observed in 2B4 cells in which Bcl-2 was overexpressed after 
treatment with dexamethasone thus demonstrating that Bcl-2 protects against 
dexamethasone induced lipid peroxidation. Using the oxidation-sensitive fluorescent 
compound, 5,6-carboxy-2,7- dichlorofluorescin, Hockenbery and coworkers were able 
to assess the production of peroxides in 2B4 cells with and without Bcl-2
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overexpression following dexamethasone treatment. However, Bcl-2 did not affect 
peroxide production following dexamethasone treatment in cells constitutively 
expressing Bcl-2, compared to those which did not; this demonstrates that, although 
Bcl-2 can protect against the damaging effects of reactive oxygen species, it does not 
prevent their generation.
Jun kinase (JNK) and p38 kinase are members of the mitogen- 
activated protein kinase super-family and are activated in response to stimuli such as 
UV radiation, removal of growth factors, oxidants, osmotic shock and inflammatory 
cytokines (Minden et al. 1994; Xia et al. 1995; Raingeaud et al. 1995). The stress- 
regulated signalling pathways that activate JNK or p38 are integrated by another MAP 
kinase protein, ATF2. cJun can function as a heterodimer with ATF2 which is 
regulated by JNK and the p38 (MAP) kinase (Livingstone et a l 1995; Raingeaud et 
al. 1995). Induction of JNK has been shown to activate c-Jun prior to induction of 
apoptosis in the PC 12 pheochromocytoma cell line by withdrawal of Nerve Growth 
Factor (NGF) (Xia et al. 1995). PC 12 cells transfected to constitutively overexpress 
Bcl-2 protein did not die on removal of serum and did not show an increase in JNK 
level thus suggesting that Bcl-2 works upstream from JNK, preventing its activation 
in order to protect cells from apoptosis (Park et al. 1996).
A number of other proteins have also been shown to have a role in the 
regulation of apoptosis such as Bax, Bad, Bcl-xS, Bcl-xL and Bag-1. Bcl-x mRNA is 
alternatively spliced, encoding a larger protein, Bcl-xL and a smaller protein Bcl-xS. 
Bcl-xL is consists of 233 amino acids and has a high degree of homology to Bcl-2, 
however the region with the highest homology is deleted in Bcl-xS giving a protein 
consisting of 170 amino acids (Boise et al. 1993). Bcl-xL was shown to protect 
against growth factor withdrawal in an IL-3 dependant murine cell line FL5.12 
whereas Bcl-xS was shown to inhibit the ability of Bcl-2 to protect against cell death. 
Bcl-xS did not have any effect on the viabilty of cells or the rate of cell death when 
expressed alone. Bcl-xS mRNA is found at high levels in cells which undergo a rapid 
turnover such as developing lymphocytes, whereas Bcl-xL is found in tissues 
containing long-lived post-mitotic cells such as the adult brain. Thus, regulation of 
the expression and splicing of Bcl-x mRNA plays an important role in the regulation 
of apoptosis. Bax, another member of the Bcl-2 family, has extensive homology to
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Bcl-2 and forms homodimers or heterodimers with Bcl-2 (Oltavi et al. 1993). 
Overexpression of Bax resulted in acceleration of apoptosis in FL5.12 cells induced 
by cytokine deprivation although it did not induce cell death itself The ratio of Bcl-2 
to Bax appears to be important in determining the sensitivity of a cell to a death 
stimulus (Oltavi et al. 1993). When Bcl-2 predominates, the cells are protected from 
apoptosis, however when Bax is in excess, the cells are sensitive to the death 
stimulus. Bad has some homology to Bcl-2 but unlike the other Bcl-2 members it does 
not appear to form homodimers and lacks the C-terminal signal-anchor sequence 
responsible for positioning the other Bcl-2 family members to intergral membranes 
(Yang et al. 1995). Bad forms dimers with Bcl-xL and Bcl-2 but does not form dimers 
with Bax, Bcl-xS or Mcl-1. Bad competes with Bax for binding to Bcl-xL and 
overexpression of Bad was shown to inhibit the protective effect of Bcl-xL against 
programmed cell death. Bad also competes with Bax for binding to Bcl-xL but had no 
effect on the ability of Bcl-2 to protect against apoptosis. Overexpression of both Bcl- 
2 and Bag-1 gave a greater protection against a variety of death inducing stimuli than 
when either protein was expressed alone (Takayama et al. 1995). However, Bag-1 is 
not a member of the Bcl-2 family and does not contain any homology to Bcl-2 or any 
of the other Bcl-2 family members.
1.9 Selenium compounds induce apoptosis in vitro
In vitro studies have demonstrated the ability of various selenium compounds to 
induce apoptosis in a number of cell lines. Administration of selenite and the novel 
synthetic selenium compound p-XSC resulted in the cells displaying characteristics 
typical of apoptosis such as condensation of the cytoplasm and nuclei and formation 
of apoptotic bodies (Thompson et al. 1994). Electrophoresis of extracted DNA 
resulted in a DNA ladder which is a typical feature observed in apoptotic cells. 
Administration of SDG to mouse erythroleukaemic (MEL) cells resulted in membrane 
blebbing and many of the cells became bi- or multi-nucleate with many of the nuclei 
appearing damaged (Lanfear et al. 1994). Cells were further examined for apoptosis 
using two dye flow cytometry. This method involves the staining of cellular DNA 
with the fluorescent dyes propidium iodide and Hoechst 33242. Viable cells are able
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to exclude both dyes whereas necrotic cells and cells in the late stages of apoptosis 
are stained with both dyes. Changes in the membrane permeability of apoptotic cells 
are such that Hoechst stain is able to penetrate the membrane but the propidium 
iodide is excluded from the nucleus. Further analysis by agarose gel electrophoresis 
showed that cells treated with SDG produced a DNA ladder, thus providing more 
evidence that SDG induces apoptosis in MEL cells. Lanfear and coworkers (1994) 
also demonstrated that SDG treatment caused an induction of p53 protein in the 
ovarian cell line A2780, which expresses wild type p53. However, it seems unlikely 
that the p53 pathway is essential for the induction of apoptosis since SDG induces 
apoptosis in MEL cells which possess mutant p53 and thus do not have the normal 
p53 response mechanism.
Thus, the mechanism by which selenium compounds induce apoptosis is not 
understood. The reduction of selenite by its reaction with glutathione is proposed to 
result in the generation of superoxide anion which is then converted to H20 2 by 
superoxide dimutase (Seko et al. 1989 ). Thus it has been hypothesised that selenite 
could induce apoptosis by the production of H20 2 and thereby activate oxidative 
stress pathways. However, comparison of apoptosis induced by SDG and H20 2 in the 
mouse mammary cell line C57 suggested that these compounds induce apoptosis by 
different mechanisms (Wu et a l 1995). The stochiometry of the reaction proposed by 
Seko implies that one molecule of H20 2 would be produced for each molecule of 
SDG with undergoes reduction, yet the concentration of H20 2 required to give an 
equivalent kill to that of SDG is 200 fold higher. Moreover, treatment of cells with 
SDG resulted in the formation of 50 and 150kb DNA fragments, whereas treatment 
with H20 2 resulted in the formation of 560kb fragments only. Wu and coworkers 
(1995) also demonstrated that a mutant C57 clone, B19, was resistant to SDG but was 
not cross resistant to cell death induced by H20 2 thus providing further evidence that 
the two compounds act by separate mechanisms.
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1.10 Possible Mechanisms of chemoprevention by selenium compounds
Epidemiological studies and animal studies have shown selenium to have 
anticarcinogenic properties but the mechanism involved is not understood. Selenium 
is essential for the synthesis of glutathione peroxidases which act as antioxidants, 
preventing damage by peroxides and free radicals to cellular macromolecules. It has 
been hypothesised that increasing selenium intake could increase glutathione activity 
and thus inhibit carcinogenesis. The activity of cellular GPx in the mammary gland in 
rodents is generally saturated at approximately 0.1 ppm Se to 0.2 ppm Se for rats 
(Lane and Medina 1993; Ip and Daniel 1985) whereas the concentration required for 
inhibition of carcinogenesis is usually approximately 2 ppm. The activity of plasma 
glutathione peroxidase in rats was also found to be saturated at selenium adequate 
levels; 0.104 mg Se/kg (Bermano 1996). Therefore, it seems unlikely that the activity 
of these enzymes is responsible for the anti-carcinogenic properties of selenium.
Selenium was found to strongly depress the mutagenic effects of acridine 
orange and DMBA in the Ames Salmonella/microsome mutagenicity test (Martin et 
al. 1981). A maximum reduction of histidine revertants following acridine orange 
treatment was observed with 5 ppm sodium selenite which is a comparable level to 
that administered in vivo. However, a much higher concentration of 44 ppm was 
required to achieve maximum inhibition of the mutagenic effects of DMBA. 
Selenium has been shown to reduce DNA adduct formation by N-hydroxyamino- 
fluorene (NOHAAF) and acetylamino-fluorene (AAF) when administered to the diet 
of rats as 4 ppm sodium selenite 3 days before carcinogen treatment (Daoud and 
Griffin 1978). This study also found that selenite caused a 50% decrease in p- 
nitrophenol-sulphotransferase activity which is responsible for NOHAAF and AAF 
activation and an increase of 100% in glucoronyltransferase activity, an enzyme 
involved in detoxification mechanisms. The decrease in carcinogen binding to DNA 
on selenium administration can therefore possibly be attributed to a decrease in 
activation, and an increase in detoxification processes. Selenite was also shown to 
reduce DNA adduct formation following DMBA treatment in vivo; however, 3 weeks 
of pre-treatment with selenium was required before any inhibition was observed 
(Ejadi et al. 1989). This study also showed that selenium affected the metabolism of
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the carcinogen since a decrease in the levels of anti-dihydrodiol epoxide adducts was 
observed.
Although the initiation phase of tumorigenesis is most sensitive to selenium 
administration, the post-initiation phase of tumorigenesis is also inhibited by 
selenium. Selenite can also inhibit tumorigenesis induced by direct acting carcinogens 
which do not require metabolic activation such as N-methyl-N'-nitro-N- 
nitrosoguanidine (MNNG) (Kobayashi et al. 1986) and N-methyl-N-nitrosourea 
(MNU) (Thompson and Becci. 1980) as well as virally induced tumorigenesis, 
(Milner 1985) providing further evidence that alteration in metabolism is not solely 
responsible for the anticarcinogenic properties of selenium molecules.
Although at low concentrations selenium is able to stimulate cell growth, at 
higher concentrations it has been shown to be cytotoxic (Medina and Obom 1984; 
Webber et al. 1985). The ability of selenium to inhibit cell growth in vitro may be 
related to its antitumorigenic properties in vivo. At concentrations which are growth 
inhibitory, selenium has been shown to inhibit the synthesis of DNA, RNA and to a 
lesser extent protein synthesis. (Gruenedel and Cruikshank. 1979). 
Selenodiglutathione (SDG), the primary metabolite of selenite has been shown to 
inactivate elongation factor 2 (EF2) in an in vitro cell free system (Vemie et al. 
1974). It was hypothesised that SDG was able to react with the sulphydryl groups 
present in EF2 resulting in its deactivation. Incubation with glutathione reductase was 
shown to reverse the inhibition of EF2 activity (Vemie et al. 1975). As it can be 
expected that glutathione reductase is present in most cells this raises some doubt as 
to whether SDG would inhibit EF2 in vivo. Examination of protein synthesis using 
rabbit reticulocyte lysate found no inhibitory effect of selenite on EF2 activity, 
although selenite was observed to inhibit the activity of the Met-tRNA binding factor, 
eukaryotic initiation factor 2 (eIF-2) (Safer et al. 1980).
Thioredoxin is reduced by a reaction with NADPH catalysed by thioredoxin 
reductase and is then able to act as a hydrogen donor and reduce protein disulphides, 
thus regulating the activity of other protein and enzyme systems. Selenite and SDG 
are able to oxidise mammalian thioredoxin and thioredoxin reductase and act as 
competitive inhibitors of thioredoxin reductase (Bjomstedt et al. 1992). When 
selenite is added to the reaction mixture, a lag phase is observed before NADPH
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oxidation occurs. However, no lag phase occurs when SDG is added to the reaction 
mixture, suggesting that SDG or one of its metabolites is the substrate for the enzyme, 
rather than selenite. Ribonucleotide reductase is required for the production of 
precursors for DNA replication and its activity is regulated via thiol redox control by 
the thioredoxin system. Thus, inhibition of the thioredoxin system could explain how 
selenium is able to inhibit DNA synthesis. SDG was shown to inhibit reduction of 
dCDP by ribonucleotide reductase, possibly by inhibition of thioredoxin reductase; 
however the possibility of SDG directly acting on the active site of ribonucleotide 
reductase can not be excluded.
1.11 Novel Selenium Compounds
Although selenium compounds have been shown to have anti-carcinogenic properties, 
a major problem is that toxicity occurs at levels not much higher than the therapeutic 
dose. Studies have been performed in which selenium is administered as naturally 
occurring forms such as selenium enriched garlic, with the hope of delivering 
selenium more safely. The garlic is grown in soil enriched with sodium selenite and 
results in the accumulation of high levels of an organic form of selenium in the garlic. 
By using a DMBA and MNU mammary carcinogenesis model in rats, selenium 
enriched garlic extract was found to provide significant protection against tumour 
formation, in contrast to natural garlic extract, which was found to have no effect on 
mammary carcinogenesis (Lu et al. 1996). It can therefore be assumed that the anti­
cancer activities of the selenium-enriched garlic are provided by an active selenium 
compound. Selenomethyl selenocysteine has been identified as the major amino acid 
in selenium enriched garlic (Cai et al. 1995) and it has also been shown to have 
similar biological activities to selenium-enriched garlic extracts such as cell cycle 
blockade, cell morphology and DNA fragmentation patterns when examined in vitro 
(Lu et al. 1996). Both selenite and selenomethyl selenocysteine have been 
demonstrated to inhibit cell growth and induce cell death in a mouse mammary 
carcinoma cell line (Lu el al. 1995). Selenite was shown to cause single strand DNA 
breaks in a dose-dependant manner, which is considered a measure of genotoxicity. 
Selenite undergoes reductive metabolism resulting in the formation of superoxide and
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other reactive oxygen species which are thought to be responsible for the DNA single 
strand breaks and thus cell death. Double strand breaks are also observed shortly after 
the appearance of single strand breaks following selenite treatment (Lu et al. 1995). 
In contrast, selenomethyl selenocysteine appears to exert its anti-cancer effects in the 
absence of genotoxicity as it was able to induce double strand breaks and cell death in 
the absence of single strand breaks. Further evidence that selenite and Se- 
methylselenocysteine inhibit cell growth and induce cell death by different 
mechanisms is provided by their ability to cause cell cycle arrest at different stages of 
the cell cycle. Selenite has been shown to cause cell cycle blockade in the S/G2-M 
phase of the cell cycle, whereas selenomethyl selenocysteine has been demonstrated 
to cause a G1 cell cycle arrest (Lu et al. 1995). Selenomethyl selenocysteine has also 
been shown to cause a 74% decrease in cyclin E-cdk2 content and a 57% decrease in 
cdk2 kinase activity whereas treatment with selenite resulted in no change in the 
binding of cyclins D l, E or A to cdk2 and a 30% increase in cdk2 kinase activity 
(Sinha et al. 1996).
A number of groups have tried to develop novel selenium compounds with 
chemopreventive activity but without toxic side effects. Replacement of the oxygen 
and/or sulphur atom in certain naturally occurring compounds has been shown to 
enhance the anti-cancer properties of that compound. A study which compared the 
synthetic organoselenium compound benzyl-selenocyanate (BSC ) with its sulphur 
analogue benzyl-thiocyanate (BTC) in their ability to inhibit DMBA induced 
mammary carcinogenesis in rats found that the organoselenium compound BSC 
significantly inhibited tumour incidence and multiplicity whereas its sulphur analogue 
BTC had no effect on mammary carcinogenesis (Nayini et al. 1989). This 
demonstrates that the selenium molecule is essential for the anticarcinogenic 
properties of the compound. However, the body weights of rats fed diets containing 
BSC were lower than control rat thus suggesting systemic toxicity.
An analogue of BSC, l,4-phenylenebis(methylene)selenocyanate (p-XSC), has 
been developed which has been shown to have greater chemopreventive properties 
with a lower incidence of toxicity. In a DMBA-induced mammary carcinogenesis 
study in the rat, p-XSC was shown to have a higher chemotherapeutic index 
(calculated by the ratio of the maximum tolerated dose, to the dose required to give
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50% inhibition of tumour yield) than BSC, methyl selenocyanate (KSeCN) and 
selenite (Ip et al. 1994). Lung tumour multiplicity in mice in which tumours were 
induced by 4-(methylnitrosamino)-l-(-3-pyridyl)-l-butanone (NNK), a component of 
tobacco, was significantly inhibited by 5, 10 and 15 ppm p-XSC administered in the 
diet (El-Bayoumy et al. 1993). Sodium selenite was not found to have any effect on 
lung tumour induction by NNK. No apparent toxicty was observed at 15 ppm p-XSC 
which is three times the level of selenium given as selenite which can be tolerated in 
mice. An in-vitro study which compared the accumulation of p-XSC and selenite in 
cells demonstrated that mouse mammary carcinoma cell lines were able to tolerate 
higher levels of selenium when it was administered as p-XSC as opposed to selenite 
(Thompson et al. 1994).
It is not understood how p-XSC provides protection from carcinogenesis but 
its ability to induce apoptosis (Thompson et al. 1994), inhibit the activity of 
prostaglandin E2 (Reddy et al. 1992) and prevent formation of DNA adducts (El- 
bayoumy et al. 1995), may be related to its anti-cancer properties.
A number of aliphatic selenocyantes were developed which varied 
only in the length of the aliphatic chain, CH3-(CH2)n-SeCN in which n = 0, 2, 4, or 6 
and were tested for their ability to inhibit DMBA induce mammary cancer in the rat 
(Ip et al. 1995). A reduction in tumour yield and tumour incidence was observed 
without any effect on the growth rate of the animals. The chemopreventive potency of 
the compound increased with chain length, as did the ability to inhibit the formation 
of DNA binding adducts. The optimum aliphatic carbon side was found to be a pentyl 
group as there was no further increase in the chemopreventive effects by the addition 
of an extra carbon group.
1.12 Aims of project
The mechanism by which selenium has its anticarcinogenic effects is not understood 
although it is likely to be related to its ability to inhibit cell growth and induce 
apoptosis. The mechanism by which selenium induces apoptosis is also not 
understood although it has been hypothesised that selenite induces cell death during 
its reduction to hydrogen selenide by the generation of reactive oxidant species 
resulting in oxidative stress. Evidence from other studies suggests that certain organic
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molecules such as selenomethyl selenocysteine may induce cell death by a different 
mechanism to selenite.
Bcl-2 has been shown to inhibit the ability of a number of stimuli to cause 
apoptosis possibly by its ability to prevent the effects of reactive oxygen species and 
peroxides, therefore determination of whether Bcl-2 could inhibit selenium induced 
apoptosis may provide a further insight in to the mechanism involved in selenium 
induced apoptosis.
Most studies investigating the effects of selenium on carcinogenesis have used 
the inorganic selenium compound selenite which is taken up from the soil by plants 
and converted to inorganic selenium compounds. The primary metabolite of selenite 
formed by its reaction with glutathione, selenodiglutathione (SDG) has been shown to 
be more potent than selenite and can induce apoptosis rapidly unlike selenite which 
induces apoptosis after a lag phase. Co-administration of glutathione with selenite 
results in the abolition of the lag phase thus suggesting that to induce apoptosis 
selenite must first be metabolised to SDG. Thus SDG was chosen to be the selenium 
compound used to test if Bcl-2 can protect against selenium induced apoptosis.
A number of groups have attempted to synthesize novel selenium compounds 
which have the anticarcinogenic properties of selenite but without the toxicty 
observed with selenite administration. One such compound, p-XSC has been shown 
to be more potent at inducing apoptosis than selenite and have greater 
chemopreventive properties yet appears to be less toxic than selenite. It was also 
therefore interesting to deduce if p-XSC induced cell death could be inhibited by 
overexpression of Bcl-2.
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M ateria ls and M ethods
2.0 Materials
Tissue culture
Supplier: Beatson Institute Central Services 
-PBS, PE
Supplier: Life Technologies Ltd, Paisley,U.K.
-Glutamine, G418, Special Liquid Medium, Trypsin
Supplier: Sigma, Poole, UK.
-RPMI Medium, Bufferall, Sodium Bicarbonate, Sodium Pyruvate
Supplier: Flowgen, Kent, U.K. 
-electroporation cuvettes
Chemicals
l,4-phenylenebis(methylene)selenocyanate (p-XSC) was kindly donated by Dr. El-Bayoumy, 
American Health Foundation, Valhalla, New York
Supplier: Boehringer, Lewes, U.K.
-Cesium Chloride
Supplier: Dupont, Stevenage, U.K.
- 35s -g s h
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Supplier: Fisher Scientific, Loughborough, U.K.
-Ammonium acetate, Ammonium persulphate, Butanol, DMSO, EDTA 
Glacial Acetic Acid, Glucose, Glycerol, Glycine, Hydrochloric acid, 
Isopropanol, Methanol, Sodium Acetate, Sodium Dodecyl Sulphate, Sodium 
Chloride, Sodium hydroxide
Supplier: Life Technologies Ltd., Paisley, U.K.
-Tris.HCl, Protein molecular weight markers
Supplier: James Burrough (F.A.D.) Ltd.
-ethanol
Supplier: Severn Biotech Ltd.,
-30% Acrylamide
Supplier: Sigma, Poole, U.K.
-Reduced glutathione (GSH), Sodium selenite, Nickel Chloride, Ninhydrin stain 
TEMED, Tween 20, Ethidium Bromide, Aprotinin, Leupeptin, 
PhenylmethylsulphonylFluoride (PMSF)
Chromatography Materials
Supplier: Bio-rad Laboratories Ltd., Hemel Hempstead, U.K. 
-AG50W H+ resin
Supplier: Sigma, Poole, U.K.
-G10 Sephadex beads
Supplier: Camlab, Cambridge, U.K.
-TLC plates
Antibodies
Supplier: Amersham International pic, Little Chalfont, U.K. 
-anti rabbit Horse Radish Peroxidase conjugated
Supplier: PharMigen Deutschland GmbH, Hamburg, Germany 
-Rabbit anti-mouse Bcl-2 antiserum
Kits
Supplier: Promega, Southampton,U.K.
-MTT assay kit
ECL reagents, dyes,
Supplier: Ammersham International pic, Little Chalfont, U.K. 
-ECL membranes, ECL detection reagents
Supplier: Sigma, Poole, U.K.
-bromophenol blue, ficol, Hoechst 332258 stain
Supplier: BDH Ltd.,Poole,UK.
-Giemsa Stain
Supplier: Life Technolgies Ltd., Paisley, U.K. 
- 1Kb DNA ladder
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M ethods
2.1. Tissue culture techniques
2.1.1 Maintenance and Growth of Cell Lines
MCF7 cells were grown in a humidified incubator at 37°C in an atmosphere of 5 % 
(v/v) C 0 2/0 2. Cells were grown in RPMI medium with 10% foetal calf serum and 
buffered to a constant pH using 1% Bufferal.
500 ml RPMI medium:
-400 ml distilled H20 , 45 ml 1 Ox RPMI, 50 ml Foetal Calf Serum,
5 ml glutamine, 5 ml sodium pyruvate, 13.3 ml sodium bicarbonate,
5 ml bufferal
Confluent cells were trypsinised every 3-4 days. For a T25 tissue culture flask growth 
medium was removed by aspiration and cells washed with 5 ml PBS. 0.5 ml PE 
containing 0.25% trypsin was added and left for 1-2 min at room temp and then gently 
agitated to detach cells from the flask surface. Trypsin was inactivated by the addition 
of RPMI/10% FCS and the cells seeded at an appropriate concentration into new 
flasks. Cells were grown in this manner for a maximum of 3 months after which time 
they were replaced from frozen stocks.
2.1.2 Storage of cells
Cells were trypsinized, resuspended in growth medium and pelleted by centrifugation 
for 5 min at 1000 rpm in a Centaur 2 MSE centrifuge. The cells were resuspended in 
RPMI/20%FCS/10%DMSO at a concentration of 5xl06- lxlO7 per ml and alloquoted 
into 1 ml Nunc cryotubes. The cryotubes were wrapped in cotton wool and allowed to 
cool slowly overnight (about 1 °C/min) to -70°C after which they were transferred to 
liquid nitrogen. Ampoules of cells were thawed by placing into water at 37°C, the 
cells transferred to a universal container, fresh RPMI added and the cells pelleted as 
described above to remove DMSO. The cells were then resuspended in growth 
medium and seeded into dishes.
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2.1.3 Testing for mycoplasma
NRK 49 fibroblast cells were seeded into 60mm dishes at 104 cells per dish in 4 ml 
SLM/10%FCS. 2 ml of media which had been in contact with MCF7 cells for a 
minimum of 2 days was added to the dishes. One dish of NRK cells was set up in 
parallel without conditioned medium as a control. The NRK cells were then incubated 
for 3-4 d in a humidified incubator at 37°C/5%(v/v) C 0 2 .The medium was removed 
and the cells washed twice with PBS. 2.5 mis PBS and 2.5 mis of fixative (3 volumes 
methanol: 1 volume glacial acetic acid) were slowly added to each dish and then 
poured off. Cells were then washed twice more with 5 ml fixative for 10 min and the 
dishes left to drain. To each dish 5mls of PBS containing 0.05pg/ml Hoechst 33258 
stain was added and then left for 10 min at room temperature. The stain was removed 
and the dishes washed twice with distilled water. The cells were then examined for 
mycoplasma using a Leitz Wetzlar fluorescent microscope, using a water immersion 
lens.
2.2. Kill curve assays
2.2.1 MTT Assay
Cells were seeded in to 96 well microtitre plates at 500 cells per well and incubated 
overnight at 37°C in a humid atmosphere with 5%(v/v) C 02. The medium was 
aspirated and fresh medium containing SDG or pXSC at the appropriate concentration 
was added to each well. Samples were prepared in quadruplicate. SDG or pXSC was 
added to medium immediately before addition to wells to ensure minimum 
degradation and plates were then incubated at 37°C overnight. 15 pi of MTT dye was 
added to each well and then the plates were incubated at 37 °C for 4 h. 100 pi 
solubilisation stop solution was then added to each well and the plates left overnight 
at room temp. The optical density of each well against wells containing medium only 
was measured using a Dynatech MR7000 microtitre plate reader.
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2.2.2 Clonogenic growth assays
250 cells were plated into 60 mm dishes and incubated overnight at 37°C to allow 
cells to adhere. Increasing concentrations of SDG or pXSC was then added to each 
dish and the cells incubated at 37°C for 14 d. The medium was then removed, the 
cells washed with PBS and fixed by the addition of 3 ml methanol for 20 min. The 
methanol was discarded, the plates gently rinsed with distilled water and 3 ml of 
Giemsa stain was added to the dishes and left for 15 min. The stain was then poured 
off and the dishes rinsed with H20 to remove excess stain. The number of giemsa 
stained colonies on each dish was then counted.
2.3. Preparation of Bcl-2 expressing clones
2.3.1 Transfection of cells with Bcl-2 expressing vector
lxlO7 MCF7 cells were pelleted by centrifugation and resuspended in 1ml 
RPMI/10%FCS. 10 pg of pSSFV bcl2-2n human expression vector DNA (kindly 
donated by Dr Korsmeyer, Howard Hughes Medical Institute, St Louis, USA) was 
added and 0.8 mis was then transferred to an electroporation cuvette. Electroporation 
was then carried out using a Biorad gene pulser at 640 V.cm'1, 960 pF. The contents 
of the electroporation tube were then transferred to a T175 flask containing 
RPMI/10%FCS. After 48 h, the transfected cells were selected for by the addition of 
the selection marker, G418, at 0.15 mg.ml'1.
2.3.2 Ring cloning
Following electroporation, cells were plated on 90 mm petri dishes at about 50 cells 
per dish and incubated for 7-14 days in RPMI containing 0.15 mg.mf1 of the selection 
marker, G418, so that individual colonies, containing the pSSFV bcl2-2n human 
expression vector, could be selected. Medium was removed by aspiration and cells 
were washed with PBS. Colonies were selected using a ring to surround the colony 
attached to the petri dish with silica gel. Colonies were detached by the addition to 
the ring of 100 pi of 0.25% trypsin in PE and transferred using a pasteur pipette to a 6 
mm petri dish containing RPMI70.15mg.mr1 G418.
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2.4. Large scale preparation of plasmid DNA
2.4.1 Transfection of E.coli
Competent E.Coli cells were obtained from Dr. C. Bartholomew (Beatson Institute 
For Cancer Research, Glasgow, UK). 200 pi of E.coli cells and 1 pi pSSFV bcl2-2n 
plasmid DNA were added to falcon tubes and then left on ice for 60 min. The tube 
was transferred to a waterbath at 42°C for 2 min to heat-shock the cells. 1ml L-broth 
was added and the tube left for a minimum of 5 min on ice and then transferred to a 
shaking 37°C incubator for 60 min. 5 or 10 pi of E.coli suspension was mixed with 
100 pi of L-Broth and then spread across the surface of an agar plate containing 50 
pg/ml ampicillin. The agar plates were then incubated upside down at 37°C. A colony 
was selected using a sterile toothpick and added to a universal tube containing 5 ml L- 
Broth with ampicillin at 50 pg/ml. The E.coli were grown overnight in a shaking 
incubator at 37°C. The E.coli were then added to a conical flask containing 250 ml of 
‘Terrific Broth’ and ampicillin at 50 pg/ml and incubated overnight in a shaking 
incubator at 37°C.
2.4.2 Harvesting of E.coli
Solutions:
Solution 1 50 mM glucose, 25 mM Tris.Cl (pH 8), 10 mM EDTA
Solution 2 0.2 M NaOH, 1% SDS
Solution 3 60 ml potassium acetate, 11.5 ml acetic acid, 28.5 ml H20
The E.coli were transferred to centrifugation tubs and spun at 5,000 rpm for 15 min at 
4°C in a Sorvall RC-SB superspeed centrifuge (Dupont). The pellet was resuspended 
in 10 ml solution 1 and left on ice for a minimum of 5 min. 20 ml of solution 2 was 
added and the mixture incubated on ice for 5 min. 15 ml of solution 3 was added and 
the mixture incubated on ice for a further 10 min. The mixture was then centrifuged 
at 5,000 rpm for 15 min at 4°C. 0.6 volumes of isopropanol was added to the tub, the 
contents mixed well and incubated for 15 min at room temp. The DNA was recovered
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by centrifugation in a Sorvall rotor at 4000 rpm for 15 min at room temp. The 
supernatant was discarded and the pellet resuspended in 8 mis TE.
2.4.3 Purification of plasmid DNA.
To 8 mis of DNA in TE exactly 8.8g of CsCl and 0.8 ml of lOmg/ml ethidium 
bromide were added. The solution was mixed well before it was transferred to an 
ultracentrifugation tube and centifuged at 45,000 rpm in a Sorvall Ultracentrifuge 
OTD combi for 36 h at 20°C. Two bands were then visible of which the lower band 
comprising closed circular DNA was collected. A second CsCl gradient-ethidium 
bromide was performed with centrifugation overnight at room temp at 55,000 rpm 
and again the lower band of DNA collected and transferred to fresh tube.
2.4.4 Removal of Ethidium Bromide
An equal volume of water-saturated butanol was added to the plasmid DNA and the 
solution mixed thoroughly. The upper red phase, containing ethidium bromide was 
removed and discarded. This was repeated 4-6 times until the pink colour 
disappeared. 4 volumes of distilled water and 2.5 volumes of ethanol was added to the 
extract and left for a minimum of 2 h at -20°C. The extract was then spun at 10,000 
rpm in a Beckman centrifuge for 20 min at 4°C, the supernatant discarded and the 
DNA resuspended in 100 pi TE. The extract was transferred to dialysis tubing which 
had been presoaked for a minimum of 1 h in distilled water. The dialysis tubes were 
suspended in 0. IX TE and incubated overnight at 4°C.
2.4.5 Quantitation of DNA by spectrophotometric analysis
A 1:100 dilution of pSSFV bcl2-2n DNA in TE was transferred to a Quartz cuvette 
with a 1 cm pathlength and the absorbance at 260 nm and 280 nm measured against a 
blank of TE using a spectrophotometer(Beckman Du650). A reading of 1.0 at 260 nm 
was assumed to be equivalent to 50 pg/ml for plasmid DNA. DNA with a ratio of 
260/280 between 1.8 and 2.0 was considered to be pure.
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2.4.6 Confirmation of identity of plasmid by digestion with restriction enzymes
1-2 jug plasmid pSFFV-bcl2 2n DNA was incubated with appropriate restriction 
enzymes and buffer for 3 h at 37°C. 1% (w/v) agarose was dissolved in TAE ( 0.04M 
Tris-acetate, 0.001M EDTA, pH 8.0), boiled and then poured in to a gel caster and 
allowed to set at room temp. 4 pi of loading buffer (0.25% bromophenol blue, 0.25% 
xylene cyanol FF, 15% Ficoll) was added to each sample and loaded in to the wells of 
the agarose gel. A 1Kb DNA ladder was run in parallel as a size marker. 
Electrophoresis was carried out at 150V for 1-2 h using TAE as running buffer. After 
electrophoresis DNA was stained by soaking in dH20  with 0.5 pg/ml ethidium 
bromide for 15 min and then soaking in dH20  for 15 min to remove excess ethidium 
bromide. DNA fragments were then viewed by a UV transilluminator and recorded as 
a photoimage.
2.5. Western Blotting
2.5.1 Preparation of protein to test for Bcl-2 expression
MCF7 cell clones transfected with the pSSFV bcl2-2n expression vector and selected 
with G418 at 0.15mg.ml‘1, were grown to confluence in a T175 flask. The cells were 
trypsinised, pelleted by centrifugation at 1,000 rpm in a Centaur 2MSE centrifuge and 
resuspended in ice cold PBS. Cells were pelleted and reuspended in 100 pi of ice cold 
suspension buffer, containing protease inhibitors (Suspension buffer: 100 mM NaCl, 
10 mM Tris-HCL 10 mM, pH 7.6, 1 mM EDTA, pH 8.0). and then an equal volume 
of 2x SDS gel loading buffer (2x SDS gel loading buffer: 100 mM Tris, 4% SDS, 4% 
p mercaptoethanol, 20% glycerol, 0.2% bromophenol blue) was added. The 
suspension buffer was previously autoclaved and protease inhibitors were added 
immediately before use (100 pg/pl PMSF, 1 pg/pl aprotinin, 1 pg/pl leupeptin). The 
sample was boiled for 5 min and then sonicated using a Soniprep 150 MSE to shear 
chromosomal DNA. The samples were then spun at 13,000 rpm in a microcentrifuge 
and the supernatant transfered to a fresh tube. Samples were frozen at -70°C until 
required.
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2.5.2 SDS-poIyacrylamide gel electrophoresis
Proteins were separated by SDS polyacrylamide gel electrophoresis according to 
Laemmli et al. (1970). For separation of Bcl-2 protein a 15% polyacylamide gel was 
prepared as follows.
15 % polyacrylamide gel (50ml)
ml
h 2o 11.5
30% acrylamide mixture 25
1.5 M Tris (pH 8.8) 12.5
10% SDS 0.5
10% ammonium persulphate 0.5
TEMED 0.02
The 15% acrylamide gel mixture was pippetted between two glass plates using gel 
casting apparatus, a layer of water saturated butanol added to the surface and the gel 
allowed to set at room temp. The butanol was removed and the gel surface rinsed with 
distilled water . A stacking gel was prepared, pippetted on top, a comb was inserted 
and it was allowed to set.
5% Stacking gel
ml
H20 6.8
30% acrylamide mix 1.7
1.0 M Tris (pH 6.8) 1.25
10% SDS 0.1
10% ammominum persulphate 0.1
TEMED 0.01
The gel was transferred to a gel tank which was subsequently filled with running 
buffer (Tris glycine).
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Tris Glycine - 25 mM Tris
250 mM glycine 
0.1% SDS
The comb was removed and the wells flushed with Tris glycine to remove any non­
polymerised acrylamide and any bubbles were removed from beneath the glass plate. 
Protein samples and molecular weight markers in lx  SDS loading buffer were boiled 
for 5 min. 20 pi lysate (from a confluent T175) or 5 pi molecular weight markers and 
were loaded into each well. Electrophoresis was carried out at 150-200V for 2-3h.
2.5.3 Transfer of protein to nitrocellulose membrane
12 pieces of 3 mm Whatman paper were cut to the size of the gel and 6 pieces soaked 
in anode 1 solution (0.3 M Tris; 20% methanol, pH 10.4), 3 pieces soaked in anode 2 
solution (25 mM Tris; 20% methanol, pH 10.4) and 3 pieces soaked in anode solution 
3 (40mM 6-amino-n-hexanoic acid; 20% methanol, pH 7.2) for 10 min. Hybond ECL 
nitrocellulose membrane was soaked for 5 min in distilled H20. The proteins were 
transferred from the acrylamide gel to the nitrocellulose membrane using a semi-dry 
blotter as described by Figure 2.1. Transfer was carried out at 12V for 90 min. The 
nitrocellulose was then blocked in TBS-0.1% Tween20 containing 10% Marvel 
overnight at 4°C.
TBS- 1000 ml pH 7.4 
8g NaCL 
0.2g KC1 
3g Tris base
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Figure 2.1
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2.5.4 Detection of BcI-2 protein by Enhanced Chemi-luminescence
The blocking buffer was discarded and the nitrocellulose membrane incubated in 
rabbit anti-mouse Bcl-2 diluted 1:2000 with TBS-Tween 20 in 10% Marvel for 3 h at 
room temp. The antibody was removed and the membrane washed 3 times with TBS- 
Tween 20 in 10% Marvel for 20 min. The nitrocellulose membrane was incubated 
with anti-rabbit Horse Radish Peroxidase-conjugated antibody for 1 h at room temp 
and then washed 3 times with TBS-Tween in 10% marvel for 20 min and twice for 5 
min in TBS-Tween 20 at room temp 5 ml of enhanced chemi-luminescence (ECL) kit 
solution 1 and solution 2 were mixed and added to the surface of the membrane. After 
1 min the ECL mixture was removed, the membrane wrapped in Saran wrap and 
autoradiograhic film placed over the membrane in the dark room for 30 min. To show 
equal loading of protein, the nitrocellulose membrane was stained for 2 min with 
amido black which was then rinsed with tap H20.
2.6 Measurement of GSH concentration in FCS
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GSH concentration was measured by the method of Tietze (1969). A calibration curve 
was prepared by analysis of calibration samples at 0, 2, 10, 50, 100 and 250 pM GSH
dissolved in 125 mM phosphate EDTA buffer (125 mM NaH2P 0 4.2H20 , 125 mM 
Na2H P04.2H20 , 6.3 mM EDTA, pH 7.5) in order to calculate the concentration of 
GSH in FCS. 200 pi of calibration sample or FCS (1:10 dilution) was added to 700 pi 
of 0.3 mM NADPH dissolved in 125 mM phosphate EDTA buffer and 100 pi of 6m 
M 5,5’- dithio-bis-(2-nitrobenzoic acid) (DTNB) dissolved in 125 mM phosphate 
EDTA buffer. Samples were equilibrated to 30°C and transferred to plastic cuvettes. 
The reduction of GSH was initiated by the addition of 10 pi of glutathione reductase 
(8.5 U/ml) to each cuvette and the reaction monitored by measuring the change in 
A412 for 1 min.
2.7. Synthesis and purification of SDG
2.7.1 Synthesis of selenodiglutathione (SDG)
SDG was synthesised and purified according to the method of Ganther (1971). A trace 
amount of 35S-GSH (10 pi of a 3:10 dilution of 35S-GSH with a specific activity of 
310 Ci/mmol [3.6 pCi total]) was added to 4 ml 0.1M GSH. 0.1 M Na2Se03 dissolved 
in 1 ml ice-cold 0.1 M HC1 was then added to the GSH, the mixture was left on ice for 
15 min and titrated to pH 4.5 by the addition of about 100 pi 2 M sodium acetate. 
This reaction results in the formation of SDG and oxidised glutathione (GSSG). Trace 
amount of 35S-GSH was required in order to monitor SDG in subsequent purification 
procedures.
2.7.2 Separation of SDG and GSSG
500 g of AG50W H+ resin was gently washed in distilled H20  until the washes ran 
clear. The resin was then washed with I M HC1 and then thoroughly washed with 
distilled H20  until the pH of the washes returned to 7. The resin was then washed
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with 0.1 M NaOH and again rinsed with distilled H20 until the pH of the washes 
returned to 7. Approximately 150 g of the resin was set aside and later used for the 
concentration of SDG. The remaining AG50W resin was washed in 0.1 M sodium 
acetate, pH 4.7, and then soaked in 2x volumes of 0.1 M sodium acetate, 0.3 M NiCl2, 
pH 4.7, in order to saturate the resin with nickel. The resin was poured in to a 2.6 cm 
diameter glass column and allowed to pack under gravity to a height of approximately 
60 cm. Running buffer (0.1 M sodium acetate, 0.01 M NiCl2, pH 4.7) was pulled 
through the column by a peristaltic pump at a rate of 2.5 ml/min for a minimum of 1 h 
in order to equilibrate the column. Running buffer was run into the column and the 
sample was loaded to the top of the column carefully using a Pasteur pipette without 
disturbing the resin. After the sample had run in to the column, running buffer was 
added to the top of the column which was then connected to the running buffer 
reservoir ensuring that no air was introduced in to the system. The A240 of the column 
eluate was measured by a Biorad UV monitor connected to Biorad Ecno chart 
recorder (model 1325) and 4 ml fractions were collected following the onset of the 
first peak using an Ultrurac 2070 fraction collector (LKB). 200 pL aliquots from these 
fractions were then measured for 35S-radioactivity in order to determine which 
fractions contained SDG. The fractions containing SDG were then pooled and were 
titrated to a pH of <3 using 5 M HCL and stored overnight at 4°C .
2.7.3 Concentration of SDG and removal of nickel
150 g previously washed AG50W resin (see section 2.7.2) was poured in to a 4.5 cm 
glass column and allowed to pack under gravity. 0.1 M formic acid was pulled 
through the column at a rate of 2.5 ml/min by a peristaltic pump until the A240 became 
constant. The buffer was allowed to run from the very top of the column and the 
SDG was carefully loaded on the column without disturbing the resin. The SDG was 
then run in to the column and excess 0.1 M formic acid was run through the column 
until the A240 of the column eluate became constant. Under acidic conditions SDG 
becomes adsorbed to the resin; the SDG was then eluted with 0.1 M ammonium 
acetate pH 5.6. The A240 of the column eluate was measured and fractions collected 
and monitored as described in section 2.7.2. Fractions containing SDG were pooled 
and stored overnight at 4°C.
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2.7.4 Buffer Change
100 g GlO-sephadex beads were allowed to swell in water overnight. The G10 beads 
were then poured in to a 4.5 cm diameter glass column and allowed to pack under 
gravity. Distilled H20 was pulled through the column by a peristaltic pump at a rate of 
0.7 ml/min until the A24o became constant and a maximum of a third of the volume, of 
the column, of SDG was loaded on to the column carefully using a glass pipette. SDG 
was run in to the column and distilled H20 was then run through the column at 0.7 
ml/min. The A240 of the column eluate was again measured and fractions were 
collected and monitored for 35S radioactivity as described above. 50 pi aliquots from 
fractions were used to measure the conductivity using a Osmomat 030 (Gonotec) in 
order to ensure that all salt had been removed from the SDG sample. The fractions 
containing SDG were pooled and 2 M acetic acid was added to give a final 
concentration of 10 mM. The SDG was then stored in aliquots at -20°C.
2.8. Analysis of SDG purity
The purity of SDG was analysed using thin layer chromatography (TLC) and by 
measuring the absorbance spectrum.
2.8.1 Thin Layer Chromatography
An air tight glass chamber was pre-equilibrated with a 2:1:1 mixture of butanol : 
acetic acid : water. 6 pi of the SDG sample was spotted on to a SIL G TLC plate and 
run in parallel to 3 pi of 820 pM SDG (previously synthesised in the laboratory by 
L.Wu), 2 pi 2 mM GSSG, 3 pi 1 mM GSH and lpl of a 1:10 dilution of the original 
mixture of SDG and GSSG. Chromatography was carried out in the glass chamber 
until the solvent front nearly reached the top of the TLC plate. The TLC plate was 
then allowed to dry and the chromatography repeated. Once the solvent front had 
again nearly reached the top of the plate it was allowed to dry and was stained with 
0.2% ninhydrin in ethanol and was then heated in the oven (Hybaid) for 15 min at 
80°C to enable the pink/purple colour to develop.
45
2.8.2 Absorbance spectum of SDG
The spectrophotometer Du650 (Beckman) was calibrated with distilled H20 in a 
quartz cuvette with a 1cm pathlength over a range of 220-420nm. The absorbance 
spectrum of SDG was measured over the above range and compared to that of the 
previously synthesised SDG.
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3. R esu lts
3.1 Aims of project
The mechanism by which selenium has its anticarcinogenic effects is not understood 
although it is likely to be related to its ability to inhibit cell growth and induce 
apoptosis. The mechanism by which selenium induces apoptosis is also not 
understood although it has been hypothesised that selenite induces cell death during 
its reduction to hydrogen selenide by the generation of reactive oxidant species 
resulting in oxidative stress. Evidence from other studies suggests that certain organic 
molecules such as selenomethyl selenocysteine may induce cell death by a different 
mechanism to selenite.
Bcl-2 has been shown to inhibit the ability of a number of stimuli to cause 
apoptosis possibly by its ability to prevent the effects of reactive oxygen species and 
peroxides, therefore determination of whether Bcl-2 could inhibit selenium induced 
apoptosis may provide a further insight in to the mechanism involved in selenium 
induced apoptosis.
Most studies investigating the effects of selenium on carcinogenesis have used 
the inorganic selenium compound selenite which is taken up from the soil by plants 
and converted to inorganic selenium compounds. The primary metabolite of selenite 
formed by its reaction with glutathione, selenodiglutathione (SDG) has been shown to 
be more potent than selenite and can induce apoptosis rapidly unlike selenite which 
induces apoptosis after a lag phase. Co-administration of glutathione with selenite 
results in the abolition of the lag phase thus suggesting that to induce apoptosis 
selenite must first be metabolised to SDG. Thus SDG was chosen to be the selenium 
compound used to test if Bcl-2 can protect against selenium induced apoptosis.
A number of groups have attempted to synthesize novel selenium compounds 
which have the anticarcinogenic properties of selenite but without the toxicty 
observed with selenite administration. One such compound, p-XSC has been shown 
to be more potent at inducing apoptosis than selenite and have greater 
chemopreventive properties yet appears to be less toxic than selenite. It was also 
therefore interesting to deduce if p-XSC induced cell death could be inhibited by 
overexpression of Bcl-2.
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3.2 Synthesis of SDG
SDG was produced by the reaction described by Ganther (1971). Briefly, sodium 
selenite was reacted with glutathione at a ratio of 1:4 under acidic conditions for 15 
min at 4°C. A trace amount of 35S radiolabelled glutathione was included in the 
reaction to enable detection of SDG in subsequent purification procedures. The 
reaction results in the formation of SDG and oxidized glutathione (GSSG) which 
were separated by loading on to a chromatography column containing AG50W H+ 
resin saturated with nickel chloride (NiCl2). SDG has a greater affinity for nickel than 
GSSG and so passed through the column at a slower rate thus enabling the separation 
of the two compounds by collection and analysis of fractions. The A4 2 0 of the eluate 
was measured and two peaks were observed. Fractions were collected and further 
analysed for radioactivity (figure 3.1). The fractions of the second peak containing 
SDG were pooled. The SDG was concentrated and the NiCl2 removed by passing 
through a second column containing AG50W H+ resin. SDG binds to the resin under 
strong acidic conditions and can then be eluted by the addition of ammonium acetate, 
which is a weak acid. Measurement of the A4 20 and radioactivity enabled detection of 
eluate fractions containing SDG. SDG was then run through a third column 
consisting of G10 Sephadex beads equilibrilated with water to remove salt. Again the 
SDG was monitored by UV absorbance and radioactivity and the conductivity 
measured to ensure that salts were adequately removed.
The purity of SDG was analysed by thin layer chromatography by running in 
parallel with GSH, GSSG, SDG which had previously been synthesised in the lab in 
1993 and the original mixture of reaction products (figure 3.2). SDG purity was 
further analysed by recording the UV absorbance spectrum from 220 - 420nm (figure 
3.3). The UV absorbance spectrum was comparable to that published by Ganther 
(1971) indicating that purification was successful and the TLC analysis performed 
indicated that synthesis and purification of SDG had also been a success.
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Figure 3.1
Separation of SDG and GSSG by column chromatography
Na2Se03 was reacted with GSH at a ratio of 1:4 under acidic conditions on ice. The products 
of the reaction, SDG and GSSG were separated by column chromatography using an AG50W 
H+ resin saturated with nickel and 0.1M sodium acetate/0.01M NiCl2j pH 4.7 as elution 
buffer. The A420 of the eluate was monitored and 4ml fractions collected of which 200pl 
aliquots were subsequently analysed for 35S radioactivity. GSSG and SDG eluted as the 1st 
and 2nd peaks respectively.
1 2 3 4 5
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Figure 3.2 Thin layer chromatography to determine purity of SDG .
The TLC plate was stained with ninhydrin.Samples were loaded as follows: 
Lane (1) 3pl 820pM SDG previously synthesised and purified by L.Wu in 1993 
Lane (2) 6pl purified SDG 
Lane (3) 2pl 2mM GSSG 
Lane (4) 3pl ImM GSH
Lane (5) 1 pi of a 1:10 dilution of original reaction mixturecontaining GSH and 
sodium selenite mixed at 4:1
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Figure 3.3
Absorbance spectrum of SDG over a range of 220 - 420 nm
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3.3 Standardisation of conditions for SDG induced cell death.
Preliminary experiments showed variation in the concentration of SDG required to 
kill cells between experiments, despite consistent results with replicates within an 
experiment. It was important to determine what factors were involved in causing this 
inter-experimental variation in order to achieve a more standardised assay.
3.3.1 Effect of pH on SDG induced cell death
Since SDG is known to be unstable at alkaline conditions. Unavoidable changes in pH 
during culturing cells in bicarbonate buffers could be the cause of the variation in the 
apparent potency of SDG between experiments. To test this, an MTT assay was 
performed on MCF7 cells growing in tissue culture medium to which small quantities 
of HCL or NaOH were added to give pH ranging from pH 5.9 to 7.4, to determine the 
concentration of SDG required to kill 50% of cells at different pH (figure 3.4). An 
MTT assay involves the metabolism of 3-[4,5]-dimethylthiazol-[2-yl]-2,5- 
diphenyltetrazolium bromide, resulting in a purple colour change which is a function 
of the metabolic activity of cells and thus is an indirect measure of cell viability. The 
MTT assay performed showed that at pH 5.9 the cells were dead or had very little 
metabolic activity (Fig. 3.4). At pH 6.4, the cells did not appear to be growing or 
attach to the dish as well as they did at the higher pHs. In this experiment the highest 
growth rate, as determined by the MTT assay, was in medium at pH 7.4. There was 
little difference in the concentration of SDG (3.25-3.5pM) required to kill 50% of 
cells over pH range 6.4 - 7.4 thus SDG can be considered to be stable over this pH 
range. Future experiments were buffered at pH 7 using 1% bufferal to ensure that the 
pH did not rise above pH 7.4 due to fluctuating C 02 levels and thus limiting the risk 
of SDG degradation which may occur at a higher pH.
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Figure 3.4
MTT assay to show the effect of pH on SDG induced cell death
500 cells were plated on to each well o f  a 96 well plate and incubated over night at 37°C to 
adhere. Tissue culture medium was prepared at pH 5.9, 6.4, 6.9 and 7.4 and the appropriate 
amount of SDG was added to give concentrations ranging 0-5.5pM immediately before use. 
The medium from each well was removed and replaced with lOOpl o f  medium containing 
SDG at a specific pH and the plates incubated overnight at 37°C. Samples were prepared in 
quadruplicate. 15pl of MTT dye was added to each well, the plates incubated for 4 hours at 
37 "C and then lOOpl solubilisation stop solution added. The optical density was measured 
against wells containing medium only. Error bars represent standard deviation from the mean.
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3.3.2. Effect of Foetal Calf Serum concentration on SDG induced cell death
The concentration of FCS in tissue culture medium has previously been shown to 
effect the ability of the p-XSC to induce cell death (Ronai et al. 1995). To determine 
if FCS concentration effects SDG potency, SDG was dissolved in medium containing 
different concentrations of FCS and was added to cells which were incubated 
overnight after which time an MTT assay was performed (figure 3.5). SDG was most 
potent when administered to medium containing 5% FCS. A greater concentration of 
SDG was required to induce cell death when added to medium containing 10% FCS. 
With medium containing 15% FCS, SDG was unable to induce cell death over the 
range of concentrations studied. This experiment demonstrates that the level of FCS 
in the medium greatly influences the concentration of SDG required to give a 50% 
kill.
At low concentrations of FCS, normal cell growth can be impaired. 
The optimum concentration of FCS for growing MCF7 cells is considered to be 
approx. 10% FCS and as SDG was adequately potent at this concentration of FCS, 
subsequent experiments were carried out with medium containing 10% FCS in order 
that the same medium could be used for growing cells in mass culture and for cloning 
experiments.
3.3.3. Effect of Glutathione on SDG and pXSC induced cell death.
As GSH has been shown to be required for the metabolism of SDG to its persulphide 
derivative, it is possible that variation in GSH concentrations between batches of FCS 
could result in the variations in the apparent SDG potency observed between 
experiments (Seko 1989). To determine if co-administration of GSH could enhance 
SDG induced cell death an MTT assay was performed using medium containing 5 and 
lOpM GSH (figure 3.6). The potency of SDG was greatly increased by the addition of 
GSH. Addition of 5 and lOpM GSH to 3.5pM SDG reduced cell viability to 
approximately 35 and 15% respectively, compared to approximately 100% viability 
without glutathione.
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500 cells were plated into each well of a 96 well plate and left over night at 37°C to adhere. 
The medium from each well was removed and replaced with l O O j l i I  of medium containing 
SDG and 5, 10 or 15 % FCS and the plates incubated overnight at 37°C. Samples were 
prepared in quadruplicate and an MTT assay performed. The data are expressed relative to 
the optical density o f  the wells incubated with medium only. Error bars represent standard 
deviation from the mean.
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500 cells were plated on to each well o f  a 96 well plate and left over night at 37°C to adhere. 
The medium from each well was removed and replaced with lOOpl o f  medium with GSH and 
SDG at the stated concentrations and the plates incubated overnight at 37°C. Samples were 
prepared in quadruplicate and an MTT assay performed The data is expressed as a 
percentage o f  the optical density o f  the cells incubated OpM SDG. Error bars represent 
standard deviation from the mean.
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As the GSH concentration has been shown to enhance the potency of SDG it 
was investigated if it could equally enhance the potency of the novel synthetic 
selenium compound pXSC by performing an MTT assay (figure 3.7). No difference 
in the concentration of pXSC required to kill MCF7 cells was observed when 5pM of 
GSH was added to the tissue culture medium. A higher concentration of pXSC was 
required to kill cells on addition of 20pM GSH to tissue culture medium. 50% of 
MCF7 cells were killed at 6pM pXSC whereas on co-administration of 20pM GSH 
the concentration of pXSC required to kill 50% of MCF7 cells was increased to 
approximately lOpM pXSC. Thus 20pM GSH was found to be protective against cell 
death induced by pXSC.
3.3.4. Determination of the concentration of GSH in foetal calf serum.
As alteration of GSH concentration effects the potency of SDG, it was hypothesised 
that fluctuations of GSH in foetal calf serum could be responsible for experimental 
variations in SDG potency. Calibration samples containing 0-100pM GSH were 
prepared and the absorbance at 412nm was measured during a reaction with 
glutathione reductase (Fig. 3.8). By measuring the absorbance of FCS following a 
reaction with glutathione reductase, FCS was found to contain negligible quantities of 
GSH. However, in order to demonstrate for certain that fluctuations in GSH 
concentration between serum bottles could not be responsible for causing the 
variation in SDG potency observed between previous experiments, it would be 
necessary to determine the concentration of GSH in the batches of FCS previously 
used.
3.4 Effect of Bcl-2 on cell death induced by selenium compounds
The aim of the following experiments was to determine if Bcl-2 could inhibit cell 
death induced by SDG and p-XSC. The ability of SDG and p-XSC to induce cell 
death was compared in MCF7 cells which over-expressed Bcl-2, with MCF7 cells 
which expressed normal levels of Bcl-2.
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500 cells were plated per well o f  a 96 well plate and left over night at 37°C to adhere. The 
medium from each well was removed and replaced with 100pl of medium with GSH and 
pXSC at the stated concentration and the plates incubated overnight at 37°C. Samples were 
prepared in quadruplicate and an MTT assay performed. The data is expressed as a 
percentage o f  the optical density of the cells incubated with OpM p-XSC. Error bars represent 
standard deviation from the mean.
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200j.il GSH (O-lOOpM) or 200pl of a 1:10 dilution o f  FCS was added to 700j.il 0.3mM 
NADPH buffer and 1 OOjliI 6mM DTNB dissolved in 125 mM phosphate EDTA buffer. The 
reduction o f  GSH was initiated by the addition of lOpl o f  glutathione reductase (8.5U/ml) to 
each cuvette and the reaction monitored by measuring the change in A412 for 1 min. The 
peak absorbance for each sample over the 1 min period is shown above. The estimated 
absorbance o f  undiluted FCS is plotted.
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To attain over-expression of Bcl-2, MCF7 cells were transfected with a bcl-2 
cDNA expression vector, clones containing the expression vector were selected and 
those demonstrated to over-express Bcl-2 protein were used in subsequent 
experiments. MCF7 cells were also transfected with an empty vector to act as a 
control.
3.4.1 Production of Bcl-2 expressing clones
The pSFFV human bcl2-2n plasmid expression vector ( Hockenbery 1990) and a 
control pSFFV vector which did not contain the bcl-2 cDNA, were obtained from Dr 
Korsmeyer (Howard Hughes Medical Institute, St Louis, USA). As only a small 
amount of plasmid DNA was available, it was first necessary to amplify the plasmid 
DNA by growing it up in E.coli.
Competent E.coli were transformed with the bcl-2 cDNA plasmid, harvested 
and the plasmid DNA recovered. Plasmid DNA was purified by double cesium 
gradient-ethidium bromide ultra-centrifugation. A restriction digest of both plasmids 
with ECoRI, gave DNA fragments of the size expected from examination of the 
restriction enzyme map and thus verified that the correct plasmid had been isolated.
MCF7 cells were transfected with pSFFV bcl2-2n vector and vector control by 
electroporation and stable transfectants selected for by the addition of G418 48 h after 
electroporation. Since the vector contains the neomycin resistance gene, G418 
resistant colonies were allowed to grow up for 3 to 4 weeks before being isolated by 
ring cloning. Selected colonies were trypsinised and seeded in to petri dishes and 
grown up in order that protein lysate could be prepared.
In order to determine which clones were expressing Bcl-2, protein lysates 
were prepared from 8 clones transfected with pSFFV bcl2-2n and 2 clones transfected 
with pSFFV vector control. The proteins in the lysate were separated on an SDS- 
polyacrylamide gel by electrophoresis and transferred on to a nitrocellulose 
membrane using a semi-dry blotter. Bcl-2 protein was detected by incubation of the 
nitrocellulose membrane with rabbit anti-mouse Bcl-2 antiserum, which also has 
affinity for human Bcl-2 protein. An incubation with anti-rabbit horse raddish 
peroxidase-conjugated antibody was performed enabling detection of Bcl-2 protein by
Figure 3.9
Western Blot to show Bcl-2 expression in MCF7 cell transfectants
Protein lysate from MCF7 cells transfected with pSFFV human bcl2-2n plasmid 
expression vector by electroporation and grown up in 0.15 mg.mF1 G418, was loaded 
on to an SDS-polyacrylamide gel and proteins separated by electroporesis. Protein 
was transferred to nitrocellulose membrane and incubated overnight at 4°C in 
blocking buffer. The nitrocellulose membrane was incubated with a 1:2000 dilution of 
rabbit anti-mouse Bcl-2 antibody for 3 h and then for 1 h with anti-rabbit HRP- 
conjugated antibody at room temp. Bcl-2 was detected by enhanced chemi- 
luminesence (Figure A). The nitrocellulose membrane was stained with Amido Black 
to show equal loading of protein (Figure B). BX and AP were transfected with empty 
vector controls; P3, D2B, C2C, J2, E2C, C1B, D2A and C2B were transfected with 
the bcl2 expression vector .
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electrochemical luminescence (ECL) (figure 3.9A). A number of clones were shown 
to be positive for Bcl-2 expression including D2B, C2C, J2, E2C and D2A. An amido 
black stain of the nitrocellulose membrane was prepared to show equal loading of 
protein on the gel (Fig. 3.9B).
3.4.2 Effect of Bcl-2 expression on SDG induced cell death
To determine whether Bcl-2 can prevent cell death induced by SDG, the ability of 
SDG to induce cell death was compared in MCF7 cells expressing normal levels of 
Bcl-2 and in MCF7 cells over-expressing Bcl-2. The ability of SDG to induce cell 
death was assessed by performing an MTT assay and a cloning assay. A cloning assay 
was also performed as this is a more direct method of measuring cell viability as it a 
measure of the cloning efficiency of cells.
MTT assay
MCF7 cell transfectants expressing Bcl-2 and MCF7 cells transfected with vector 
control were plated on to 96 well plates and allowed to adhere overnight. Two 
experiments were performed; the first compared the effects of the Bcl-2 expressing 
MCF7 clones, C2C and J2, with the BX MCF7 clone which was transfected with 
control vector only. The second experiment compared the effects of D2B, a bcl-2 
positive clone, with AP, a clone containing vector control only. Tissue culture 
medium was removed from each well and replaced with medium containing SDG at 
concentrations ranging from 0 to 3.5 pM SDG and the cells incubated overnight at 
37°C. An MTT assay was performed and the results are shown in Figure 3.10. In 
both experiments there was no significant difference in the SDG concentration 
required to kill 50% of positive or negative Bcl-2 expressing MCF-7 clones.
Cloning Assay
Cloning assays were performed in which approximately 250 cells were seeded on to 
petri dishes and allowed to adhere before treatment with SDG. Three cloning assays 
were performed to determine if Bcl-2 can protect against SDG induced reductions in 
the cloning efficiency of the cells.
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500 MCF7 cells expressing Bcl-2 or vector only controls were plated per well o f  a 96 well 
plate and left over night at 37°C to adhere. Bcl-2 expressing clones include J2, C2C and D2B. 
Ap and BX are vector only controls. The medium from each well was removed and replaced 
with lOOjLil of medium cpntaiping SDG at the appropriate concentration and the plates 
ipcpbated overnight at 37°C. Samples were prepared in quadruplicate and an MTT assay 
performed. The data is expressed as a percentage of the optical dep^ify p f  the peljs incubated 
with OpM SDG. Error bars represent standard deviation from the mean.
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Figures (a) and (b) illustrate two separate experiments comparing clones J2 and BX, and 
Figure (c) illustrates a comparison o f  clones D2b and AP. 250 MCF7 cells expressing Bcl-2 
(D2B or J2) or vector only controls (AP or BX) were plated on petri dishes and left overnight 
at 37°C to adhere. SDG was added to each dish to give the required concentration and the 
cells incubated at 37°C for 14 days. Dishes at each concentration were prepared in 
quadruplicate. The colonies were stained with Giemsa stain and the number o f  colonies 
counted. Error bars represent standard deviation from the mean.
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In the first cloning assay using (Figure 3.1 la), the concentration of SDG required to 
kill 50% of the Bcl-2 positive clone, J2, was approximately 3.9pM, compared to cells 
containing vector control (clone BX), for which 3.65pM SDG was required to kill 
50% of cells. However, on repetition of the experiment (figure 3.11b) there appeared 
to be no difference in the sensitivity of Bcl-2 expressing clones compared to Bcl-2 
negative clones. The concentration of SDG required to kill 50% of cells was 
approximately 3.1pM SDG for both J2 and BX clones. A third experiment was 
performed in which the Bcl-2 positive clone D2B and the Bcl-2 negative clone AP 
were compared (Figure 3.1 lc ). This experiment also showed no increased resistance 
of Bcl-2 positive clones to SDG compared to Bcl-2 negative clones.
Overall, the results of the MTT assays and the cloning assays suggest that the 
Bcl-2 expressing clones were equally sensitive to SDG as the Bcl-2 negative clones.
3.4.3 The Effect of Bcl-2 expression on p-XSC induced cell death
To determine whether Bcl-2 can prevent cell death induced by p-XSC, the ability of 
p-XSC to induce cell death was compared in MCF7 cell expressing normal levels of 
Bcl-2 and in MCF7 cells over-expressing Bcl-2. The ability of p-XSC to induce cell 
death was assessed by performing an MTT assay and a cloning assay.
MTT assay
Two MTT assays were performed in an attempt to determine if  Bcl-2 expression in 
MCF-7 cells can protect against p-XSC induced cell death. Figure 3.12 depicts the 
results of an MTT assay in which the effects of p-XSC Bcl-2 positive clones J2 and 
C2C were compared to that on the Bcl-2 negative clone BX. Although the C2C 
clones appear to be slightly more resistant to p-XSC than the BX clone, the J2 clone 
appears to be slightly more sensitive than BX clones. A second MTT assay set up to 
examine the effects of p-XSC on the Bcl-2 positive and negative clones D2B and API 
respectively, did not show any difference in the sensitivity of the two clones to pXSC.
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500 MCF7 cells expressing Bcl-2 or vector controls were plated on to each well o f  a 96 well 
plate and left over night at 37 C to adhere. Bcl-2 expressing clones include J2, C2C and D2B. 
AP and BX clones are vector only controls. The medium from each well was removed and 
replaced with 100 pi o f  medium containing pXSC at the appropriate concentration and the 
plates incubated overnight at 37°C. Samples were prepared in quadruplicate and an MTT 
assay performed. The data is expressed as a percentage o f  the optical density o f  the cells 
incubated with OpM p-XSC. Error bars represent standard deviation from the mean.
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250 MCF7 cells expressing Bcl-2 (D2B and J2) or vector only controls (AP and BX) were 
plated on petri dishes and left overnight at 37°C to adhere. pXSC was added to each dish to 
give the required concentration and the cells incubated at 37°C for 14 days. Dishes at each 
concentration were prepared in quadruplicate. The colonies were stained with Giemsa stain 
and the number o f colonies counted. Error bars represent standard deviation from the mean.
69
Cloning Assay
In order to detect any differences in the sensitivity of Bcl-2 expressing clones and 
Bcl-2 negative clones to pXSC, a cloning assay was performed using the Bcl-2 
positive clones J2 and D2B and the Bcl-2 negative clones AP and BX. The results are 
shown in Figure 3.13. D2B, AP and BX were all approximately equally sensitive to 
pXSC with 50% of cells killed at approximately 2.5pM. The Bcl-2 positive clone J2 
appeared slightly more sensitive to pXSC with 50% of cells killed at approximately 
1.75pM pXSC.
3.4.4. The Effect of Bcl-2 expression on H20 2 induced cell death
As Bcl-2 possibly prevents cell death by it's ability to prevent the effects of reactive 
oxygen species and Bcl-2 has previously been shown to prevent cell death induced by 
H20 2 in a haemopoetic cell line (Hockenbery et al. 1990), it was investigated whether 
H20 2 induced cell death could be prevented in the MCF7 cell transfectants expressing 
Bcl-2. The ability of H20 2 to induce cell death in MCF7 cells in Bcl-2 positive and 
negative clones was assessed by performing an MTT assay and a cloning assay.
MTT Assay
An MTT assay was performed using BX, a Bcl-2 negative clone and J2, a Bcl-2 
positive clone to help elucidate if Bcl-2 expression in MCF7 cells could protect 
against H20 2 induced cell death (Fig.3.14). The Bcl-2 positive clone J2 appeared to be 
slightly more resistant to H20 2 induced cell death than the Bcl-2 negative clone, BX. 
By performing a Two-Tailed Student’s t-Test, the difference in sensitivity of the Bcl-2 
positive and negative clones to H20 2 was not found to be significant at most 
concentrations, although the difference was found to be significant at 0.6 and 1,4mM
h 2o 2
Cloning Assay
An cloning assay was performed in which 250 D2B cells (Bcl-2 positive) and AP 
cells (Bcl-2 negative) were seeded on to petri dishes and left overnight to adhere. The 
cells were then treated with 0-1.0 mM H20 2 and 14 days later the percentage survival
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500 MCF7 cells expressing Bcl-2 or vector only controls were plated on to each well o f a 96 
well plate and left over night at 37°C to adhere. J2 and BX are a Bcl-2 expressing clone and 
vector only control respectively. The medium from each well was removed and replaced with 
lOOpl o f medium containing H20 2 at the appropriate concentration and the plates incubated 
overnight at 37°C. Samples were prepared in quadruplicate and an MTT assay performed.
The data is expressed relative to the optical density o f the cells incubated with medium only. 
Error bars represent standard deviation from the mean. * = significantly different i.e p< 0.05; 
Students T-test.
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250 MCF7 cells expressing Bcl-2 (D2B) or vector only controls (AP) were plated on petri 
dishes and left overnight at 37°C to adhere H20 2 was added to each dish to give the required 
concentration and the cells incubated at 37°C for 14 days. Dishes at each concentration were 
prepared in quadruplicate. The colonies were stained with Giemsa stain and the number of 
colonies counted. Error bars represent standard deviation from the mean.
was recorded (Fig. 3.15). The Bcl-2 positive clone does not appears to be more 
resistant to H20 2 than the Bcl-2 negative clone and no significant difference was 
found between the two clones using the Students t-Test.
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Discussion
Standardisation of experimental conditions for SDG and p-XSC induced cell 
death
Sodium selenite is a natural inorganic form of selenium which is metabolised in vivo 
to organic forms which can then be incorporated in amino acids selenocysteine and 
selenomethionine or can undergo a series of reduction and methylation reactions in 
order to be excreted (see Fig. 1.3). Sodium selenite kills cells in vitro after a lag 
phase which can be eliminated by GSH coadministration. Selenodiglutathione (SDG) 
is the primary product of selenite, formed by the reaction of selenite and glutathione 
(GSH) with glutathione reductase or by non-enzymatic reduction when glutathione is 
in excess (Ganther et al. 1971). Addition of SDG to cells in vitro results in rapid cell 
death without the lag phase observed with selenite and SDG is also more potent than 
selenite in vitro. Thus it was decided that SDG would be used in order to investigate 
selenium induced cell death and as it was not commercially available it was necessary 
to synthesize and purify it in the laboratory. A novel selenium compound, p-XSC has 
been synthesized which has been shown to be more potent at inducing apoptosis than 
selenite and have greater chemopreventive activity than selenite yet appears to be less 
toxic than selenite (Ip et al. 1994; Thompson et al. 1994). It was also therefore 
interesting to investigate the mechanisms of cell death by induced by p-XSC in this 
study. MCF7 cells were chosen for these experiments since they are a human 
mammaiy cell line and a large number of carcinogenesis studies testing the 
chemopreventive effects of selenium compounds have utilised a mammary tumour 
models in rodents (Lane and Medina. 1985; Ip. 1981; Horvath and Ip. 1983; 
Thompson et al. 1984).
Previously, the potency of SDG was found to fluctuate substantially between 
experiments. Cells were sometimes killed at concentrations as low as 1.75pM SDG 
yet on other occasions there was complete cell survival at lOpM. This was 
problematic when designing experiments. It was hypothesised that SDG was subject 
to decomposition but the reason for the inconsistency of this decomposition remained 
unclear. It is unlikely to be a temperature dependant effect as this is strictly 
controlled: SDG is stored on ice immediately before its addition to tissue culture 
medium which is then incubated in a 37°C incubator.
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At alkaline pH selenotrisulphides such as SDG are relatively unstable, 
degrading to the disulphide and elemental selenium (Ganther 1968).
R SSeSR--------------------------- ► RSSR + Se
SDG is considered to be relatively stable at acidic pH and so is stored in lOmM acetic 
acid, thus minimum degradation would be expected. The pH of regular bicarbonate 
buffered tissue culture medium can sometimes become quite alkaline, especially 
when transferring micro-titre plates or open dishes from incubators with a 5% (v/v) 
C02 atmosphere to laminar flow hoods during manipulations and could possibly result 
in degradation of SDG and thus cause the variation observed between experiments. 
In this study, MTT assays were performed to investigate the effects of pH on SDG 
potency. The results of the experiment showed that the potency of SDG was stable 
over the pH range studied (pH 6.4-7.4). Therefore further experiments were all 
carried out with medium buffered at pH 7.0 using Bufferal. It is likely that without 
extra buffering, the pH of the bicarbonate buffered medium could rise much higher 
than 7.4. It may be of interest to perform further experiments at which the pH of 
tissue culture medium is above pH 7.4 to prove the hypothesis that SDG degrades 
when the pH of tissue culture medium becomes too alkaline and to also determine the 
threshold pH at which degradation occurs.
The addition of glutathione (GSH) to selenite has been shown to enhance cell 
death and abolish the lag phase observed with selenite alone. In the reaction 
proposed by Seko (1989) (see figure 1.1), GSH is also shown to be required for the 
enzymatic reduction of SDG to the persulphide derivative by glutathione reductase or 
by nonenzymatic reduction of SDG when GSH is in excess. If a metabolite of SDG is 
responsible for the toxic effect rather than SDG itself, fluctuations in GSH 
concentration in the tissue culture medium could be another source of variation of 
SDG potency. In this study an MTT assay performed to investigate the effect of GSH 
on SDG potency. For the first time it was shown that addition of 5 and lOpM GSH 
substantially increased the potency of SDG. However, addition of up to 20pM GSH 
did not increase the potency of the novel synthetic selenium compound pXSC. As
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glutathione does not enhance the activity of pXSC and is not required for its 
metabolism it is likely that the ability of GSH to enhance the activity of SDG is 
related to its ability to reduce SDG to an active metabolite. If metabolism of SDG to 
an active metabolite is required to induce cell death then the metabolic capacity and 
hence growth status of the cells may be an important factor affecting the potency of 
SDG. It may be that cells in an exponential phase of growth can metabolise SDG 
more rapidly than quiescent cells. It is possible that the density of cells could effect 
their sensitivity to SDG as confluent cells may have a low metabolic rate and 
therefore activate SDG at only a very slow rate. However, preliminary work by J 
Fleming (unpublished) in C57 cells did not show any effect of density of cells on 
SDG potency.
In this study, co-administration of 20 pM GSH appeared to provide some 
protection against pXSC toxicity. Recent work by J Fleming (unpublished) has 
shown high concentrations of GSH to be protective against cell death induced by both 
SDG and pXSC; 50 pM GSH was shown to reduce C57 cell death induced by pXSC 
by approximately 50%, and 100 pM GSH was found to reduce SDG induced cell 
death by approximately 80%. SDG and pXSC are thought to induce apoptosis by 
oxidative stress so the presence of GSH at high concentrations may protect against 
cell death induced by these compounds by it’s ability to act as an antioxidant (Deneke 
et al. 1985; Hagen et al. 1988). N-acetylcysteine (NAC) which is the biological 
precursor to GSH and is itself an antioxidant, has also been shown to be protective 
against cell death induced by SDG and p-XSC (J Fleming; unpublished).
In order to determine if variation in the amount of glutathione present in FCS 
was responsible for the fluctuation in potency of SDG observed between experiments, 
an assay was performed to determine the concentration of GSH in FCS. However, it 
was demonstrated here that FCS did not contain detectable levels of GSH and so this 
was not the cause of fluctuation in SDG potency. Glutathione peroxidases require 
GSH for their activity thus raising the question as to how plasma glutathione 
peroxidase can function if there is no GSH in serum. It may be that glutathione 
peroxidase utilises another thiol present in plasma other than glutathione, one 
possible candidate being thioredoxin.
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The amount of foetal calf serum (FCS) added to the medium was previously 
found to be critical in altering the ability of pXSC, a novel synthetic selenium 
compound to induce cell death (Ronai et al. 1995). An MTT assay was performed 
here to determine if the potency of SDG was also effected by FCS concentration. The 
results show that, like pXSC, the potency of SDG is affected by the amount of FCS in 
the medium. This result is consistent with the finding of Vemie et al. (1979) who 
demonstrated that the ability of SDG to inhibit protein synthesis was reduced when 
the concentration of serum was increased from 5 to 20% with complete loss of 
inhibitory activity at 20% serum. It is possible that selenium is able to bind to 
selenium-binding proteins present in FCS: thus the greater the concentration of FCS, 
the lower the concentration of active free SDG available to cause the growth 
inhibitory effects. Alternatively, increasing the concentration of FCS could increase 
the levels of thiols which are responsible for the detoxification of SDG. In this study, 
subsequent experiments were carried out with medium containing 10% FCS and in 
experiments comparing the sensitivity of clones care was taken to use medium from 
the same bottle to minimise any minor fluctuations between batches of medium. 
However, any differences in FCS between experiments as a result of using different 
bottles of medium are negligible and are unlikely to account for the large fluctuations 
in SDG potency observed previously. The same batch of FCS was used in all 
experiments because variation in the content of various components such as thiols or 
selenium-binding proteins could occur.
Effect of Bcl-2 expression on SDG and pXSC induced cell death
Overexpression of Bcl-2 has been shown to protect against apoptosis induced by a 
variety of stimuli including UVA radiation, glucose deprivation, Fas, H20 2 and c-myc 
(Pourzand et al. 1997; Lacronique et al. 1996; Hockenbery et al. 1993; Bisonnette et 
al. 1993). Apoptosis in leukaemic cells induced by daunorubicin was delayed by 
overexpression of Bcl-2 but was not prevented (Allouche et al. 1992). In this study, to 
investigate whether Bcl-2 expression could protect against SDG induced cell death, 
MCF7 cells were transfected with the Bcl-2 expression vector pSSFV-Bcl-2n.
Overexpression of Bcl-2 protein was previously shown to protect against
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apoptosis induced by H20 2 in a haemopoetic cell line (Hockenbery et al. 1993). 
However, in the present study, only a slight protective effect from apoptosis induced 
by H20 2 was observed in the MCF7 cells transfected with pSSFV Bcl-2nl. By 
performing an MTT assay, a mild protective effect against H20 2 induced cell death 
was observed in MCF7 cells overexpressing Bcl-2, although this effect was very weak 
and was only found to be significant at two concentrations of H20 2. The results of the 
cloning assay showed no significant difference between Bcl-2 expressing clones and 
vector alone controls in their sensitivity to H20 2 induced cell death. The weak 
protective effect observed suggests that either Bcl-2 expression was either not high 
enough in the transfected clones or that Bcl-2 is unable to protect against H20 2 
induced cell death in MCF7 cells.
The MTT assay measures the change in metabolic activity of the whole 
population of cells following treatment of selenium compounds or H20 2, whereas the 
cloning assay measures the percentage of cells which are capable of proliferation. 
Following treatment with pXSC and H20 2 the metabolic activity of the population of 
cells appears to be less affected than the cloning efficiency. The cloning efficiency 
and the metabolic rate of the population of MCF7 cells, appear to be equally affected 
following treatment with SDG.
Although Bcl-2 overexpression was detected in this study by using anti-Bcl-2 
antibodies in a Western Blot, it is conceivable that this Bcl-2 protein was not 
functional. For example, it is possible that a mutation could occur during the genetic 
manipulations carried out to produce the expression vector. To determine if a 
mutation in the Bcl-2 gene had occurred it would be necessary to sequence the Bcl-2 
cDNA, in the vector used. However, it seems unlikely that a mutation is present in 
the expression vector as this vector was used sucessfully by Bissonnette et al. 1992 to 
protect against cell death induced c-Myc, therefore demonstrating that the Bcl-2 
protein produced by this expression vector is functional since the vector was not 
manipulated in any way during the growth of the plasmid stocks.
It is therefore more likely that the levels of Bcl-2 were not sufficiently high 
enough to protect against H20 2 induced apoptosis. The western blot performed in this 
study to determine which clones were overexpressing Bcl-2 showed clear bands in 
several of the clones transfected with pSSFVbcl-2n whereas Bcl-2 protein was
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undetectable in cells transfected with empty vector. This suggests that Bcl-2 
expression in the Bcl-2 positive clones was several fold higher compared with the 
controls. However, as the levels of Bcl-2 were not sufficiently high enough to protect 
against H20 2 induced apoptosis, clones expressing higher levels of Bcl-2 would need 
to be produced in order to determine if  over expression of Bcl-2 can prevent apoptosis 
induced by selenium compounds.
The mechanisms controlling cell survival and cell death are complex. 
The activity of Bcl-2 is inhibited by other Bcl-2 family members such as Bax and Bcl- 
xs (Oltavi et al. 1993; Boise et al. 1993). It is. possible that on transfection with an 
expression vector and an increase in the levels of Bcl-2 protein, the cell adapts by an 
upregulation of negative feed back pathways resulting in an increased production of 
inhibitory molecules, such as other bcl-2 family members, bax and bcl-xS (Oltavi et 
al. 1993; Boise et al. 1993. This would mean that even though levels of Bcl-2 protein 
were increased, its activity is kept in check. If this is the case, very high 
concentrations of Bcl-2 protein may be required to overcome the inhibitory action of 
such molecules. It is possible that the levels of Bcl-2 achieved in this study was 
insufficient to overcome the inhibitory action of other Bcl-2 family members. 
Alternatively, other proteins with which bcl-2 interacts with may not be at high 
enough concentrations for bcl-2 to have it’s maximal effect. Coexpression of Bcl-2 
and Bag-1 proteins has been shown to provide a greater protection against cell death 
induced by a variety of stimuli than when either protein was expressed alone 
(Takayama et al. 1995). Another explanation for the lack of protective effect by 
overexpression of Bcl-2 against SDG induced cell death could be that there was 
insufficient quantities of partner proteins such as Bag-1 which are required to enhance 
the activity of Bcl-2.
Future Experiments
It is possible that overpression of Bcl-2 is not able to inhibit cell death induced by 
H20 2 and selenium compounds in MCF7 cells. By using MTT assays, Bcl-2 
overexpression has been shown to protect against apoptosis induced by Tumour 
Necrosis Factor (TNF) in MCF7 cells (Jaatella. et al. 1995). A simple experiment to
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determine if levels of Bcl-2 are sufficient to prevent apoptosis would be to add TNF 
to the Bcl-2 expressing clones and see if the cells survived at concentrations which 
caused apoptosis in control cells. This would help determine if Bcl-2 is 
mechanistically unable to prevent cell death induced by H2C>2 and selenium 
compounds or if the levels of Bcl-2 were simply inadequate.
The MTT assays and cloning assays used in this study were unable to 
demonstrate that overexpression of Bcl-2 can confer resistance to SDG and pXSC 
mediated cytotoxicty. However, Jaatella and coworkers (1995) used an MTT assay to 
demonstrate that over expression of Bcl-2 or Bcl-x conferred almost complete 
resistance to cytotoxicty mediated by high doses of anti-fas and TNF in MCF7 cells. 
MTT assays and cloning assays are able to monitor cell death yet are unable to 
distinguish between cells dying by necrosis and those dying by apoptosis. This study 
could be improved by using an assay which more directly measures cell death by 
apoptosis such as dye exclusion flow cytometry.
Earlier work has demonstrated the ability of SDG to induce apoptosis in 
mouse erythroleukaemic (MEL) cells as judged by flow cytometry and the formation 
of nucleosomal ladders following electrophoresis of DNA on an agarose gel. Selenite 
and pXSC have previously been shown to induce typical features of apoptosis in 
mouse mammary epithelial (MOD) cells such as condensation of the cytoplasm, 
formation of nucleosomal ladders and apoptotic bodies. However, it has not been 
proven that these compounds induce apoptosis in MCF7 cells. On treatment with 
SDG and pXSC condensation of the cytoplasm in MCF7 cells was observed in this 
study. However, further experiments such as detection DNA ladder formation, 
following electrophoresis on an agarose gel or two dye flow cytometry are required to 
demonstrate that SDG and pXSC induce apoptosis in MCF7 cells rather than causing 
death by necrosis.
To further investigate the mechanism of growth inhibition by selenium 
compounds, I would be interested to investigate whether other proteins involved in 
cell death pathways effect the sensitivity of cells to cell death induced by selenium 
compounds.
ICE proteases have been demonstrated to be required for cell death induced by 
a number of compounds including TNF and Fas (Itoh el al. 1991; Oehm et al. 1992).
8 0
Unlike bcl-2, ICE-family proteases inhibitors do not effect JNK activation; JNK is a 
member of the MAP kinase family and has been shown to be nessessary for induction 
of apoptosis by a number of stimuli (Park et al. 1996). These findings suggest that 
either JNK and ICE proteins are involved in separate cell death cascades or that they 
are both involved in same signalling pathway, with ICE proteases lying down-stream 
of JNK. I would like to investigate whether inhibitors of ICE proteases, could prevent 
cell death induced by selenium compounds.
Previous work, in our laboratory has suggested that SDG treatment of an 
ovarian cell line (A2780) results in accummulation of p53 protein, a known supressor 
of cell growth (Lanfear et al. 1994). However, as SDG and p-XSC have been shown 
to induce apoptosis in cell lines which contain mutated p53, the effect of p53 
accummulation in SDG induced apoptosis remains unclear (Lanfear et al. 1994; 
Thompson et al. 1994). To investigate whether p53 mutations are able to effect the 
sensitivity of cells, to cell death induced by selenium compounds, MTT and cloning 
assays could be performed on A2780 cells (which have wild-type p53) and A2780 
cells expressing dominant negative-mutant p53 protein (generated by A. Mcllwrath et 
al. 1994; CRC Beatson Laboratories, Glasgow).
If I was to continue working on this project I would use a cell line other than 
MCF7 cells. MCF7 cells are highly adhesive to each other and clump together even 
following trypsinisation thus making it difficult to count them accurately and also 
separate in to single cells for cloning assays. Also, MCF7 cells grow very slowly in 
comparison with other cell lines which means that it can take months to grow up a 
tissue culture flask of cells from a single selected colony.
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